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Angiogenesis is a fundamental process playing an important role in various 
pathological and physiological conditions including organ development and tumor 
metastasis.  Blood vessels are primarily composed of endothelial cells.  These cells 
are mostly quiescent in adults, but can be stimulated by an excess of pro-angiogenic 
factors.  One specific pro-angiogenic factor, VEGF-A (specifically VEGF165) plays a 
key role in a variety of pathological and physiological conditions.  However, the 
molecular and cellular mechanisms by which VEGF-A regulates the complex 
fundamental process of blood vessel formation is unknown.  This study was 
undertaken to identify the immediate early genes (IEGs) induced by VEGF-A, a 
hitherto uncharted research avenue.  Differential screening of a suppression 
subtractive hybridization cDNA library potentially enriched in the IEGs induced by 
VEGF-A, led to the identification of 17 IEG transcripts.  Surprisingly, this new 
putative VEGF-A response gene set consisted of transcripts with diverse functions, 
  
including those of various transcription factors such as ATF3, EGR2 and IER2, 
growth factors, enzymes and novel genes. 
RNA Binding Motif protein 5 (RBM5) was the only putative tumor 
suppressor gene and differential apoptotic regulator identified in this new putative 
VEGF-A response gene set.  This dissertation further focuses on the then novel multi-
modular protein RBM5, whose up-regulation by VEGF-A seemed paradoxical.  
Correct localization of any protein is not only essential for its function but can also 
provide vital clues about its potential cellular role.  Although, RBM5 was previously 
shown to be localized in the nucleus, its subnuclear localization was not defined.  
Localization of RBM5 in nuclear speckles was determined using enhanced green 
fluorescent protein (EGFP) fusion constructs and colocalization studies.  Based on 
these results it can be hypothesized that RBM5 may function in pre-mRNA 
metabolism.  Additionally, site-directed mutagenesis and colocalization studies 
confirmed that nuclear localization of RBM5 is mediated by only the C-terminal 
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Angiogenesis is defined as the process by which capillaries sprout from pre-
existing vasculature or blood vessels (Ferrara,1999).  It is a fundamental process 
occurring in various physiological conditions such as wound healing, placental 
development, embryonic development and organ formation.  It also plays a key role 
in a number of pathological conditions including diabetic retinopathy, psoriasis, age-
related macular degeneration and rheumatoid arthritis (Carmeliet and Collen. 1999; 
Dvorak et al., 1999; Ferrara,1999).  Moreover, the growth of tumors and development 
of metastases depends on the de novo formation of blood vessels, that is 
neovascularization or angiogenesis (Carmeliet and Jain, 2000).  Blood vessel walls 
(vascular wall) are chiefly composed of endothelial cells (tunica intima) and mural 
smooth muscle cells, also known as pericytes (tunica media).  The endothelial cells 
(ECs) line the entire interior surface of the vascular wall forming a continuous 
monolayer of cells (figure 1).  Both arteries and veins have an additional outermost 
layer composed of collagen fibers and fibroblast cells (tunica adventitia) imparting 




supported by a basement membrane and lack the two outermost layers tunica media 


















Figure 1:  Structure of blood vessels.  Endothelial cells form the innermost layer 
(tunica intima) of blood vessels followed by a layer of smooth muscle cells (tunica 
media) and collagen fibers (tunica adventitia).  The two outermost layers confer 
rigidity to the vascular wall and are absent in capillaries.  Capillaries are composed of 
a single layer of endothelial cells supported by a basement membrane (not shown).  





Endothelial cells are normally quiescent in the adults, but are metabolically 
active and have a remarkable ability to proliferate and migrate to form new vessels 
(Ferrara, 1999; Yancopoulos et al., 2000).  In addition to angiogenesis, vascular 
endothelium plays a key role in various physiological functions such as inflammation, 
coagulation, control of hemostasis and thrombosis and also functions in the regulation 
of vascular permeability, macromolecular transport and vascular wall structure 
(Dvorak et al., 1999; Sato, 2001a).  Vascular endothelium also contributes to vascular 
tone by releasing potent vasodilators and vasoconstrictors.  The continuous release of 
NO (nitric oxide) by the vascular endothelium relaxes the smooth muscle cells and 
ensures vessel patency (Dvorak et al., 1999; Sato, 2001a). 
Angiogenesis is a complex phenomenon that involves multiple steps of 
migration, proliferation, differentiation, and morphogenesis of endothelial cells.  The 
six sequential steps thought to occur in the process of angiogenesis are: 1) vascular 
destabilization by the detachment of pericytes 2) degradation of the extracellular 
matrix by endothelial proteases such as MMPs (matrix metalloproteinases) and/or 
urokinase 3) endothelial cell migration 4) proliferation of endothelial cells 5) 
formation of tube like structure by endothelial cells and finally 6) vascular 
stabilization by reattachment of the pericytes (Sato, 2001a). 
Since the vascular endothelial cells line the inner surface of the blood vessel, 
they have long been considered to be the key component of angiogenesis (Veikkola et 
al., 2000).  A number of molecules are expressed in ECs following stimulation by 
angiogenic growth factors, leading to the final outcome of angiogenesis.  Thus, the 




for understanding the key molecular mechanisms involved in the regulation of 
angiogenesis. 
The process of angiogenesis is tightly regulated by a balance between pro-
angiogenic and anti-angiogenic factors (table 1).  Nearly twenty different angiogenic 
factors have been recognized so far, a few of which are: angiopoietin-1, bFGF (basic 
fibroblast growth factor), ephrins and VEGF (vascular endothelial growth factor) 
(Gale and Yancopoulos, 1999). 
 
Angiogenic Growth Factors Anti-Angiogenic Growth Factors 
Angiogenin Angiostatin (plasminogen fragment) 
Angiopoietin-1 Antiangiogenic antithrombin III (aaATIII) 
Del-1 Canstatin 
Fibroblast growth factors (FGF): acidic/basic Cartilage-derived inhibitor (CDI) 
Follistatin Endostatin (collagen XVIII fragment) 
Granulocyte colony-stimulating factor (G-CSF) Fibronectin fragment 
Hepatocyte growth factor (HGF) Gro-beta 
Interleukin-8 (IL-8) Heparinases 
Leptin Heparin hexasaccharide fragment 
Midkine Human chorionic gonadotropin (hCG) 
Placental growth factor Interferon alpha/beta/gamma 
Platelet-derived endothelial cell growth factor 
(PD-ECGF) 
Interferon inducible protein (IP-10) 
Platelet-derived growth factor-BB (PDGF-BB) 
Pleiotrophin (PTN) 
Interleukin-12 (IL-12) 
Proliferin Kringle 5 (plasminogen fragment) 
Transforming growth factor-alpha and beta 
(TGF-α/β) 
Metalloproteinase inhibitors (TIMPs) 
Tumor necrosis factor-alpha (TNF-alpha) Pigment epithelial-derived factor (PEDF) 





Table 1:  List of some of the pro-angiogenic and naturally occurring anti-angiogenic 
discovered so far.  This table was adapted from the angiogenesis foundation website: 
www.angio.org/understanding/understanding.html and other references (Ribatti et al., 






VASCULOGENESIS AND ANGIOGENESIS 
 
Among all these diverse physiological functions performed by the vascular 
endothelium, angiogenesis is an important process, it being crucial both in normal 
development and reproduction.  In the vertebrate embryo, the vascular system is the 
first functional organ that develops.  Blood vessels in the entire body are formed by 
two distinct but related processes, vasculogenesis and angiogenesis (Carmeliet and 
Collen. 1999; Gale and Yancopoulos, 1999).  Vasculogenesis is the first step in the 
process of vascular development followed by angiogenesis.  In vasculogenesis the 
extraembryonic mesodermal cells, also known as hemangioblasts, aggregate and form 
islands in the yolk sac, where they subsequently differentiate to form an external layer 
of endothelial cells (ECs) and an inner core of blood cells.  The outer ECs form the 
primary vascular plexus.  Similarly, the intraembryonic mesodermal hemangioblasts 
and/or angioblasts in the proximal lateral mesoderm differentiate into ECs to form the 
dorsal aorta.  Subsequently, in the process of angiogenesis, neo-vessels are generated 
from the primary vascular plexus and become distributed throughout the entire body 
to form a complex network of blood vessels (figure 2).  The final stage of the vascular 
development involves the differentiation of mesenchymal cells into pericytes which 
surround the blood vessels making them mature and stable (Carmeliet and Collen. 
1999; Saaristo et al., 2000; Yancopoulos et al., 2000; Sato, 2001b). 
In comparison to the embryo, blood vessels in adults are already stabilized.  
Sprouting of any new blood vessels (angiogenesis) is stabilized by the surrounding 




of existing vessels in a phenomenon known as collateral growth (Carmeliet, 2004).  
In adults, physiological angiogenesis occurs during wound healing and in the female 
reproductive cycle (Ferrara, 1999; Carmeliet and Jain, 2000).  Pathological 
angiogenesis can occur either due to enhanced neovascularization, characteristic of 
rheumatoid arthritis, psoriasis, diabetic retinopathy, tumor development and 
metastases, or due to insufficient vascular proliferation common in myocardial and 
limb ischemia (Carmeliet and Jain, 2000). 
 
 
REGULATORS OF ANGIOGENESIS 
 
Three different receptor tyrosine kinase systems specific for the vascular 
endothelium, the ephrins, the angiopoietin-Tie system and the VEGF/VEGFR system 
have been implicated so far in angiogenesis.  All of these systems play a varied role 
in the development of vascular system (Davis and Yancopoulos, 1999; Gale and 
Yancopoulos, 1999; Carmeliet and Jain, 2000; Dodelet and Pasquale, 2000).  VEGF 
not only acts as a specific mitogen of the vascular endothelial cells, but also is the 
most potent inducer of vascular permeability known so far.  The VEGF/VEGFR 
system also seems to be critical for the earliest stages of vasculogenesis and continues 
to play a vital role during the subsequent angiogenesis.  The angiopoietin-Tie system 
and the ephrin system act in the later stages of angiogenesis but unlike VEGF, they do 
not promote mitogenic response in ECs (Gale and Yancopoulos, 1999).  




system (Saaristo et al., 2000).  The angiopoietin-Tie and the ephrin receptor tyrosine 
kinase systems are discussed in brief below followed by an in depth review of the 




















Figure 2:  Steps involved in the formation of blood vessel during embryogenesis.  The 
three important steps are thought to be vasculogenesis, angiogenesis and vascular 
remodeling.  Also represented in this diagram are the various receptor tyrosine kinase 
systems involved – Tie/angiopoietins, Eph/ephrins and VEGFR/VEGF.  Lethality 
caused due to absence of individual functional receptor tyrosine kinase system is 





THE ANGIOPOIETIN-TIE SYSTEM 
 
Angiopoietins were the second family of growth factors discovered after 
VEGF which, similar to VEGF, displayed a very high specificity for the vascular 
endothelium.  The specificity of the angiopoietins is due to the restricted distribution 
of their tyrosine kinase receptors, Tie1 and Tie2 on the vascular endothelial cells.  
Both Tie1/2 receptors display an identical domain structure consisting of a cytosolic 
split tyrosine kinase domain and extracellular fibronectin III, EGF-like (epidermal 
growth factor like) and immunoglobulin domains (figure 3).  There are four members 
in the angiopoietin family, all of which bind to the Tie2 receptor and have a similar 
architecture consisting of coiled-coil fibrinogen domains (Davis and Yancopoulos, 
1999; Koh et al., 2002).  The angiopoietins were the prototype of a vertebrate growth 
factor family consisting of both receptor activators and blockers (figure 3) (Gale and 
Yancopoulos, 1999).  In this system, Angiopoietin-1 (Ang-1, incorporated in the 
ECM) and Angiopoietin-2 (Ang-2, secreted) are the best characterized examples of an 
activator/agonist and an inhibitor/antagonist, respectively (Davis and Yancopoulos, 
1999; Partanen and Dumont, 1999; Eklund and Olsen, 2006). 
In vitro analysis has revealed that Ang-1 does not elicit any mitogenic 
response or induce any tubule formation in cultured endothelial cells similar to 
VEGF-A (the founding member of the VEGF growth factor family), but does 
promote endothelial cell sprouting and maintains structural integrity of blood vessels 
(Reiss et al., 2005).  Ang-1 seems to act in a coordinated and complementary fashion 






















Figure 3:  Differential functions and binding properties of the two angiopoietin 
receptors Tie1 and Tie2 are illustrated.  The domain structure of the two receptors is 
identical and contains extracellular immunoglobulin domain, EGF-like repeats and 
fibronectin type III repeats along with a split cytosolic tyrosine kinase domain.  
Unlike Ang-2, Ang-1 can induce receptor phosphorylation leading to initiation of 
signaling cascades.  Function of Ang-3 and Ang-4 are not yet well defined.  This 





In vivo analysis indicated that mouse embryos lacking either Ang-1 or Tie2 have 
normal early vascular development resulting in the formation of primitive 
vasculature.  However, further remodeling and stabilization of the vasculature in 
Ang-1 or Tie2 deficient mouse embryos is severely perturbed (table 2).  This is 
thought to result from the disturbed interaction between the ECs and the smooth 
muscle cells underlying them (Davis and Yancopoulos, 1999; Gale and Yancopoulos, 
1999). 
Shortly after the cloning and characterization of Ang-1, Maisonpierre et al. in 
1997 discovered Ang-2.  Ang-2 was found to bind to the Tie2 receptor like Ang-1, 
but could not activate it similar to Ang-1.  Transgenic overexpression of Ang-2 
during embryogenesis leads to a lethal phenotype similar to that seen in embryos 
lacking either Ang-1/Tie2 (Gale and Yancopoulos, 1999).  Thus, Ang-2 was the first 
known naturally occurring antagonist of a receptor tyrosine kinase.  Unlike Ang-1, 
which is constitutively expressed in the adult, Ang-2 is highly expressed only at sites 
of vascular remodeling allowing the vessels to revert to a more plastic and an unstable 
state (Davis and Yancopoulos, 1999; Gale and Yancopoulos, 1999; Partanen and 
Dumont, 1999).  Recent studies present a more complicated context dependent action 
of Ang-2.  It is now known that Ang-2 can either result in growth or regression 
depending on the presence or absence of VEGF in the microenvironment, 
respectively (Reiss et al., 2005).  Functions of both Ang-3 and Ang-4 ligands are not 
yet clearly defined.  However, preliminary studies suggest that Ang-3 and Ang-4 
might have antagonistic and agonist functions, respectively.  Although a clear role of 











Stage of vessel 
development Causes of lethality 
VEGF-A (+/-) E11.5 vasculogenesis/ (angiogenesis) 
Reduced red blood cells; defective heart and 
aorta formation; defective vessel connectivity; 
defective sprouting 




vasculogenesis Failure of endothelial cell formation 
VEGFR2 E8.5-
E9.5 
vasculogenesis Excess endothelial cells form abnormal vessel 
structures entering vessel lumens 
VEGFR3 E10.5-
E12 
vasculogenesis Defective vessel remodeling and organization; 
irregular large vessels with defective lumens 
Ang-1 E10.5 angiogenesis Defective vessel remodeling and organization; 
and sprouting; heart trabeculation defects 
Ang-2 E12.5-
P1 
maturity Poor vessel integrity, edema, and hemorrhage 
Tie1 E13.5-
P1 
maturity Poor vessel integrity, edema, and hemorrhage 
Tie2 E10.5 angiogenesis Defective vessel remodeling organization, and 





Some defective vessel primordial; defective 
vessel remodeling, organization, and sprouting; 





Some defective vessel primordial; defective 
vessel remodeling, organization, and sprouting; 
heart trabeculation defects 
EphA2 Viable - - 
 
 
Table 2:  Gene knockout studies in mice from the VEGFR/VEGF, Tie2/Ang-1, and 
Eph/ephrins families exhibiting a variety of embryonic defects in vascular 
development.  Knockouts of VEGF and its receptors yielded defects in the early 
process of vasculogenesis and hence the mutants tend to die at early stages of 
development.  In contrast, to these results the Tie2 and Ang-1 knockout embryos die 
at later stages with normal vasculogenesis but abnormal angiogenesis.  This table was 





THE EPHRIN SYSTEM 
 
The ephrin receptors (Erythropoietin-producing human hepatocellular 
carcinoma) and their ligands, the ephrins (Eph family receptor interacting proteins), 
are the largest subfamily of receptor tyrosine kinases and consist of 16 distinct 
members (Gale and Yancopoulos, 1999; Heroult et al., 2006).  Ephrins were initially 
identified as neuronal guidance molecules but have since been implicated in arterio-
venous differentiation and tumorigenesis (Heroult et al., 2006).  Unlike other receptor 
tyrosine kinase ligands, the ephrins do not function as typical soluble ligands, but 
have to be membrane bound to activate their receptors.  Multimerization of the 
ligands by membrane attachment seems to be necessary to activate the receptors on 
adjacent cells, whereas the monomeric soluble forms act like antagonists.  All known 
ephrins are tethered to the cells in which they are expressed (Dodelet and Pasquale, 
2000; Cheng et al., 2002).  The ephrin receptors (Eph) are divided into two families A 
and B representing the nature of GPI-anchored (glycosylphosphatidyl inositol) 
peripheral membrane or transmembrane ligands, respectively (figure 4A).  
Anomalous to this generalization is EphA4 receptor which can bind to ligands from 
both families (figure 4B).  There are ten members of EphA family of receptors 
binding to six ephrin-A ligands compared to six EphB receptors binding to three 
ephrin-B ligands (Brantley-Sieders et al., 2004; Heroult et al., 2006).  EphA10 a 





















Figure 4:  The structure of ephrin ligands and receptors (A).  Glycosylated ephrin 
receptors are single transmembrane spanning domain proteins with an 
immunoglobulin-like domain on the extracellular side interacting with the respective 
ephrin ligands.  The intracellular region of the Eph receptors contains a kinase 
domain along with SAM and PDZ domains.  Eph receptors are classified into two 
families A and B depending on the GPI-anchor or transmembrane nature of the ephrin 
ligands (B).  In addition to the nine Eph receptors, a new member EphA10 has been 








The Eph receptors are glycosylated and contain multiple domains (figure 4A).  
The extra-cellular immunoglobulin-like repeats interact with the ephrin ligands 
resulting in signaling through the intracellular domains.  Phosphorylation of multiple 
tyrosine residues present in the juxtamembrane region, kinase domain and SAM 
(sterile-α-motif) domain can initiate ‘forward’ signaling cascades by binding of 
SH2/SH3 (Src-Homology-2/3) domain containing proteins.  The PDZ domain (PSD-
95 post synaptic density protein, Discs large, Zona occludens tight junction protein) 
can bind to other PDZ domain containing proteins resulting in a scaffold for further 
assembly of multiple-protein signaling complexes (Brantley-Sieders et al., 2004; 
Vearing and Lackmann, 2005; Heroult et al., 2006).  Conversely, interaction between 
Eph receptors and ephrin ligands leads to ‘reverse’ signaling due to oligomerisation 
of ephrin ligands (Lu et al., 2001; Vearing and Lackmann, 2005). 
As mentioned before, action of the Eph family members has been implicated 
in important processes such as neural guidance.  Gene knockout studies have 
suggested that the ephrins play a vital role in vascular development too (Gale and 
Yancopoulos, 1999; Dodelet and Pasquale, 2000; Heroult et al., 2006).  Ephrins 
cannot induce potent mitogenic responses from endothelial cells, but do induce 
sprouting in vivo, similar to that observed using either VEGF or angiopoietin.  Also, 
since the ephrins cannot activate their receptors unless they are membrane-bound, the 
ephrin/Eph interactions are restricted to the sites of direct cell-cell contact (Cheng et 
al., 2002). 
Venous endothelium expresses both EphB3 and EphB4 receptors in addition 




ephrin-B2 besides the expression of the EphB3 receptor at few sites (Adams and 
Klein, 2000; Cheng et al., 2002).  Mouse embryos lacking either ephrin-B2 or its 
receptor EphB4 showed severe defects in the vascular remodeling both in arterial and 
venous domains (table 2) (Gale and Yancopoulos, 1999; Heroult et al., 2006).  It is 
hypothesized that these defects arise from the bi-directional signaling mediated by the 
reciprocal expression of ephrin-B2 and EphB4 occurring between arterial and venous 
vascular beds during embryonic angiogenesis (Dodelet and Pasquale, 2000; Cheng et 
al., 2002).  Thus, the differential expression of ephrin-B2/EphB4, critical for normal 
development of vasculature seems to be partially genetically programmed in arterial 
and venous endothelium.  Sprouting, another aspect of angiogenesis responsible for in 
growth of vessels in previously avascular areas of embryos does not occur in ephrin-
B2 knockout animals (table 2).  Although a clear model of the function of ephrins in 
vascular development and angiogenesis has not yet emerged, it is hypothesized that 
antagonistic functions of EphB4 and ephrin-B2 mediate the arterio-venous 
differentiation (Dodelet and Pasquale, 2000; Cheng et al., 2002; Heroult et al., 2006). 
 
 
THE VEGF-VEGFR SYSTEM 
 
VEGF is a potent inducer of vasculogenesis and angiogenesis, but it is different from 
other endothelial growth factors in its ability to selectively stimulate the endothelial 
cells (ED50 2-10 pM for micro- and macrovascular endothelial cells) derived from 




discovered VEGF independently as vascular permeability growth factor in 1989.  
Molecular cloning of the genes encoding both these proteins revealed that these two 
proteins were the same, encoded by a single gene located on chromosome 6p21.3.  
VEGF belongs to the VEGF-PDGF (platelet derived growth factor) supergene family 
(Yancopoulos et al., 2000).  The proteins in this family (cysteine knot growth factor 
family) have precisely spaced 8 cysteine residues, conserved in the 100 amino acid 
VEGF homology domain, and all these products function as antiparallel disulfide 
linked homodimers (Karkkainen and Petrova, 2000; Veikkola et al., 2000). 
In humans, VEGF or VEGF-A (was discovered first) has nine isoforms, which 
are 121, 145, 148, 162, 165b, 165, 183, 189 and 206 amino acid proteins based on 
alternative splicing of the VEGF gene that is organized in eight exons (figure 5).  Of 
these nine isoforms, VEGF121, VEGF165 and VEGF189 are preferentially made in 
various VEGF-producing cells, including endothelial cells.  However, the mechanism 
governing the levels of various VEGF isoforms produced is unknown (Takahashi and 
Shibuya, 2005).  VEGF165 is the major form and functions as a homodimeric 
glycoprotein of 46 kDa (Ferrara and Davis-Smyth, 1997).  In contrast to VEGF165, 
VEGF165b is an endogenously produced inhibitor, which binds to VEGFR2 with an 
equal affinity but cannot activate it (figure 5) (Takahashi and Shibuya, 2005).  
VEGF121 which lacks exons 6 and 7, is a weakly acidic polypeptide and does not bind 












































Figure 5:  Comparison of structures of VEGF-A subfamily and other VEGF 
homologues.  Sites of proteolytic cleavage in VEGF-C and VEGF-D are denoted by 
arrows.  VEGF-ENZ-7 is a viral homologue encoded in the genome of Orf virus and 
binds with high affinity to VEGFR2/KDR.  Regions colored with matching colors are 






Poltorak et al. in 1997 demonstrated that another isoform of VEGF, VEGF145, that 
induces angiogenesis in mouse skin, is secreted as an approximately 41 kDa 
homodimer.  VEGF145 also inhibits binding by VEGF165 to the KDR/Flk-1 receptor in 
cultured endothelial cells (Poltorak et al., 1997).  In contrast, VEGF189 and VEGF206 
are much more basic (due to exon 6 sequence) and therefore have a greater binding 
affinity to heparan sulfate proteoglycans than VEGF-A (VEGF165) itself (figure 5) 
(Ferrara and Davis-Smyth, 1997; Ferrara, 1999).  Similar to VEGF189, but unlike 
VEGF165, VEGF145 binds efficiently to the extracellular matrix (ECM) by a 
mechanism that is not dependent on ECM-associated heparan sulfates (Eriksson and 
Alitalo, 1999; Neufeld et al., 1999). 
 
Regulation of VEGF gene expression 
The spatial and temporal control of the concentration of VEGF is of extreme 
importance since it is potent activator of the vascular endothelium.  Disruption of 
both VEGF alleles in mice leads to a complete absence of vasculature (table 2).  
Disruption of only one allele in mice leads to embryonic lethality due to severe 
abnormalities in the development of vasculature (table 2) (Gale and Yancopoulos, 
1999 Neufeld et al., 1999, Yancopoulos et al., 2000).  Some of the factors that up- 
regulate VEGF gene expression are low pO2, various cytokines such as EGF 
(epidermal growth factor), TGF-ß (transforming growth factor-beta) and KGF 
(keratinocyte growth factor) (Ferrara, 2005).  Various cell transforming events such 




as in ras and bcl-2 also result in the induction of VEGF gene expression (Ferrara and 
Davis-Smyth, 1997; Ferrara, 1999; Jośko and Mazurek, 2004). 
 
VEGF homologues 
At least five different homologues of VEGF, PlGF (placental growth factor), 
VEGF-B, VEGF-C, VEGF-D and VEGF-E have been discovered to date (figure 5) 
(Olofsson et al., 1996; Carmeliet and Collen, 1999; Eriksson and Alitalo, 1999; 
Clauss, 2000).  Recent gene knockout studies in mice have indicated that the absence 
of PlGF causes deficiencies in adult vascular remodeling (Takahashi and Shibuya, 
2005).  Whereas, mice lacking VEGF-B are normal and fertile but have hearts which 
are reduced in size, indicating that VEGF-B may be important in coronary 
vascularization and growth (Yancopoulos et al., 2000).  Transgenic overexpression of 
VEGF-C, which selectively binds to lymphatic specific VEGFR3, leads to lymphatic 
hyperplasia.  The normal physiological role of VEGF-D however, remains to be 
elucidated (Carmeliet and Jain, 2000; Yancopoulos et al., 2000). 
Selective binding of VEGF and its homologues to three different tyrosine 
kinase receptors VEGFR1-3 help in the fine-tuning and control of angiogenesis 
(figure 6).  VEGF-B and PlGF both can bind to VEGFR1, whereas VEGF-A can 
interact with both VEGFR1 and VEGFR2.  VEGF-C and VEGF-D bind both 
VEGFR2 and VEGFR3 and the viral homologue VEGF-E binds and activates only 
VEGFR2 (Eriksson and Alitalo, 1999; Shibuya and Claesson-Welsh, 2006).  In 
addition to the VEGFRs, neuropilin-1, a transmembrane protein implicated in the 




PlGF-2, VEGF-E and VEGF165 (Neufeld et al., 1999; Clauss, 2000).  In addition to 
being an endothelial growth factor, VEGF also targets monocytes, retinal epithelial 
cells astrocytes, tumor derived cell lines, hematopoietic progenitor cells, trophoblasts 
















Figure 6:  Differential binding of various VEGF homologues to three VEGFRs along 
with the two neuropilin co-receptors.  All VEGF receptors have a characteristic split 
tyrosine kinase domains and seven extracellular immunoglobulin repeats.  VEGFR1 
is also found in soluble form denoted as sVEGFR1.  VEGFR2 is the primary receptor 
eliciting the signaling cascades mediating downstream effects of vasculogenesis, 
angiogenesis and vascular permeability.  VEGFR3 is mainly found in lymphatic 
endothelial cells and plays an important role in lymphangiogenesis and embryonic 






The VEGFR family includes three receptors VEGFR1 (Flt-1), VEGFR2 (Flk-
1), and VEGFR3 (Flt-4) all belonging to the platelet derived growth factor receptor 
subfamily of receptor tyrosine kinases (Taipale et al., 1999; Karkkainen and Petrova, 
2000; Robinson et al., 2000; Yancopoulos et al., 2000; Shibuya, 2001).  The receptors 
share a common characteristic of having seven extracellular immunoglobulin 
homology domains along with a single transmembrane domain and a split tyrosine 
kinase domain at the cytoplasmic end (Shibuya, 2001). 
Of all the receptor tyrosine kinases recruited by VEGF, binding and activation 
by VEGF-A to VEGFR1 and VEGFR2 are most intensely studied.  The function of 
these two receptors in vascular development and the recruitment of individual signal 
transduction cascades are discussed below in detail.  However, the understanding 
about the manner in which signal transduction cascades induced by VEGF affect the 
corresponding stimulation of vessel growth is still incomplete. 
 
VEGFR1/Flt-1 (fms-like protein tyrosine kinase) and signaling 
VEGFR1/Flt-1 has the highest affinity to VEGF165, with a Kd of 
approximately 16-114 pM (Zachary and Gliki, 2001).  Although, VEGFR1 is a 
transmembrane glycoprotein of 180 kDa, its mRNA can be spliced to produce a 
shorter soluble protein consisting only the first six extracellular immunoglobulin 
domains (Ferrara, 1999).  This soluble sFlt-1/sVEGFR1 has the capability to bind 
VEGF with high affinity (Kd 10-20 pM) and is able to inhibit VEGF induced 




sVEGFR1 may function as a physiological negative regulator of VEGF action either 
by acting as a decoy receptor or by suppressing signaling through VEGFR2.  This 
idea is further strengthened by the fact that mice engineered for loss of VEGFR1 
(E8.5-9.0) show an excess formation of abnormally coalescing endothelial cells, 
whereas mice engineered to express a truncated form of VEGFR1 (lacking tyrosine 
kinase domain) appear to be normal (table 2) (Gale and Yancopoulos, 1999; 
Carmeliet and Jain, 2000).  Additionally, domain swapping experiments between 
VEGFR1 and VEGFR2 conducted by Gille et al. in 2000 have demonstrated that a 
short ANGG motif unique to the intracellular juxtamembrane VEGFR1 domain has 
the ability to inhibit VEGFR2 mediated signaling and cell migration (Gille et al., 
2000; Zachary and Gliki, 2001).  Also, VEGFR1 is the only receptor expressed in 
monocytes mediating both tissue factor production and monocyte chemotaxis (Heil et 
al., 2000).  Additionally, VEGFR1 induces expression of metalloproteinase and 
mediates production of urokinase and plasminogen activator inhibitor in smooth 
muscle cells (Ferrara and Davis-Smyth, 1997).  VEGFR1 expression is up-regulated 
by hypoxia via HIF-1 (hypoxia inducible factor-1) binding site upstream of its coding 
sequence (Breier, 2000). 
Even though signaling through VEGFR1 is weak and does not appear to be 
important for the biological activities such as proliferation and migration of 
endothelial cells, it is essential for normal vascular development as seen from the 
gene knockout studies (table 2).  Cunningham et al. in 1995 using yeast two hybrid 
system assays demonstrated that VEGFR1 associates with the p85 subunit of PI3K 




relevance with respect to any biological activity.  Several adaptors of the Src family 
such as Fyn and Yes have also been shown to be phosphorylated due to 
VEGF/VEGFR1 interaction (Zachary and Gliki, 2001).  Recent studies have shown 
that signaling cascades emerging from VEGFR1 as a result of stimulation by VEGF-
A or PlGF are different.  This difference might arise due to varied intracellular 
receptor confirmation or may be governed by neuropilin or heparan sulfate 
proteoglycan co-receptors mediating the availability of tyrosine residues for kinases 
(Shibuya and Claesson-Welsh, 2006). 
 
VEGFR2/KDR (kinase insert domain)/Flk-1 (fetal like kinase-1) and signaling 
VEGFR2 is a transmembrane protein of 230 kDa and has no splice variants 
unlike VEGFR1 (Veikkola et al., 2000).  As compared to VEGFR1, KDR/VEGFR2 
has a lower affinity to VEGF in the range of 0.4-1 nM (Zachary and Gliki, 2001).  
Unlike VEGFR1, VEGFR2 is indirectly regulated by hypoxia via increased 
concentration of VEGF, which in turn induces VEGFR2 gene expression (Ferrara and 
Davis-Smyth, 1997; Ferrara, 1999).  Activation of VEGFR2 in the absence of 
VEGFR1 in porcine aortic endothelial cells lacking in endogenous VEGF receptors 
leads to a mitogenic response.  Consistent with this in vitro action, VEGF and 
VEGFR2 are critical for the earliest stages in vasculogenesis (Yancopoulos et al., 
2000).  Mice engineered to lack either VEGF (VEGF-A) or VEGFR2 have very few 
endothelial and primitive hematopoietic cells and develop an abnormal vasculature, 
where major vessel tubes fail to develop in appreciable numbers leading to early 




Some of the biological functions elicited via VEGFR2 are release of tissue factor, 
chemotaxis, proliferation and sprouting of cultured endothelial cells in vitro and 
angiogenesis in vivo (Zachary, 1998; Kliche and Waltenberger, 2001).  
Corresponding to this, targeted inactivation of VEGFR2 using blocking antibodies 
leads to disruption of tumor angiogenesis and prevents DNA synthesis in response to 
VEGF (Ferrara, 1999; Carmeliet and Jain, 2000). 
Since VEGFR2/KDR is the major transducing receptor, many research groups 
have been focusing on this aspect.  Overexpression of VEGFR2 and its subsequent 
activation by VEGF in endothelial cells leads to a rapid recruitment of adaptor 
proteins such as VRAP, Shc, Nck and Grb2 along with protein tyrosine phosphatases 
such as SHP-1 and SHP-2 (figure 7) (Wu et al., 2000; Kliche and Waltenberger, 
2001; Zachary and Gliki, 2001).  The yeast two-hybrid assay and RT-PCR analysis in 
conjunction with RNase protection assays also implicate recruitment of Sck (an Shc 
homologue), HCPTPA (a low molecular weight protein tyrosine phosphatase similar 
to SHP-1 and SHP-2) and a new SH2-containing proline rich adaptor protein, which 
binds constitutively to PLCγ (phospholipase C gamma) and PI3K (figure 7) (Huang et 
al., 1999; Gelinas et al., 2002; Ratcliffe et al., 2002).  Cell proliferation subsequent to 
VEGF-A/VEGFR2 interaction via activation of ERK1/2 (p42/44 MAP kinase) 
cascade has also been demonstrated in various endothelial cells such as BMEC 
(bovine microvascular ECs) and PAE (porcine aortic ECs) (Yu and Sato, 1999; Gille 
et al., 2001).  Activation of Ras and also various isoforms of PKC (protein kinase C) 
via the PLCγ pathway and subsequent increased intracellular Ca2+ levels has also 




increased synthesis of eNOS (endothelial nitric oxide synthase).  The activation of 
eNOS can be carried out either by increased intracellular Ca2+ concentration due to 
IP3 or in a Ca2+-independent manner through the activation of Akt/PKB 
serine/threonine kinase (figure 7) (Gelinas et al., 2002).  Migration responses in 
endothelial cells are mediated through the increased production of NO and also due to 
tyrosine phosphorylation of FAK (mediated by Hsp90) and paxillin subsequent to 
VEGF stimulation (Zachary and Gliki, 2001).  The stress activated p38 MAPK and its 
downstream effector HSP27 (F-actin polymerizing factor) have been shown to be 
essential for VEGF induced motility responses and actin reorganization (figure 7) 
(Matsumoto and Claesson-Welsh, 2001). 
In addition to proliferation and migration responses induced in endothelial 
cells, VEGF also prevents apoptosis induced due to serum starvation or through 
TNFα, thereby protecting and increasing survival of endothelial cells.  Signal 
transduction cascades emerging from VEGF/VEGFR2 interaction are responsible for 
conferring this protection (Schlessinger, 2000).  This cell survival signal is transduced 
via the PI3K-Akt/PKB, which then leads to the up-regulation of anti-apoptotic 
proteins such as survivin, XIAP and Bcl-2, and inhibition of pro-apoptotic proteins 
such as BAD, FKHR1 and caspase-9 (figure 7) (Gerber et al., 1998; Veikkola et al., 
2000; Matsumoto and Claesson-Welsh, 2001; Zachary and Gliki, 2001 Karkkainen et 
al., 2002; Shibuya and Claesson-Welsh, 2006).  Other key components involved in 
this cell survival process are β-catenin, VE-cadherin (endothelial adherens junction 
protein) and αvb3 integrin expressed on angiogenic endothelial cells (Matsumoto and 























Figure 7:  Signal transduction cascades emerging from various VEGFR on 
stimulation with various VEGF homologues in BEC (blood vascular endothelial cells) 
and LEC (lymphatic endothelial cells).  The signal transduction cascades as a result of 
VEGF/VEGFR2 are stronger than those emerging from other VEGF/VEGFR 
systems.  Detailed explanation of the VEGF/VEGFR2 pathway is given in the text 
along with the references cited.  Final responses elicited by individual pathways as a 
result of VEGF-A/VEGFR2 are illustrated as boxes.  This figure was adapted from 







The VEGF165 (VEGF-A)/VEGFR2 response and migration of endothelial cells 
is further potentiated due to interaction with a co-receptor-neuropilin-1.  Neuropilin-1 
is not known to have any signal transducing ability since it possesses a short 
cytoplasmic tail.  Indeed, cells with neuropilin-1 but no VEGFR2 fail to show any 
response to VEGF.  Nevertheless gene disruption studies involving neuropilin-1 show 
that it is an important regulator of angiogenesis.  Mouse embryos lacking neuropilin-1 
die due to failure of development of cardiovascular system.  Another co-receptor, 
neuropilin-2, similar to neuropilin-1 has also been discovered (Matsumoto and 
Claesson-Welsh, 2001). 
 
VEGFR3/Flt-4 and signaling 
To date very little is known about the signal transduction cascades induced via 
VEGFR3.  However, VEGFR3 has been shown to be a component in the regulation 
of development and growth of lymphatic vasculature and also in the formation of 
primary cardiovascular network (table 2) (Clauss, 2000; Veikkola et al., 2000).  
VEGFR3 knockout mice die early in the development due to cardiovascular failure 
(Gale and Yancopoulos, 1999; Matsumoto and Claesson-Welsh, 2001).  Both VEGF-
C and VEGF-D ligands selectively activate VEGFR3 and are the key components 
involved in the regulation of lymphangiogenesis and angiogenesis.  Activation of 
VEGFR3 subsequent to ligand stimulation leads to rapid tyrosine phosphorylation of 
Shc and activation of MAPK along with increased cell motility, actin reorganization 
and proliferation, similar to the VEGF-A/VEGFR2 response (Taipale et al., 1999).  




In addition to being a marker of the lymphatic vessels, recent studies have shown that 
VEGFR3 is also expressed in tumor blood vessels during the process of 





Angiogenesis is growth of blood vessels from pre-existing vasculature.  This 
fundamental process plays an important role in various pathological and physiological 
conditions including tumor metastasis.  Vascular endothelial growth factor 
(specifically VEGF-A or VEGF165) has been found to be a primary factor, regulating 
angiogenesis and various functions of endothelial cells.  Although much research has 
been done in the field of angiogenesis, there is a dearth of knowledge regarding genes 
mediating the various downstream pleiotropic effects seen in endothelial cells 
stimulated by VEGF-A and VEGFR2 interactions.  This project was undertaken to 
identify genes, specifically the immediate early genes (IEGs) induced by VEGF-A.  
This dissertation is divided in three parts.  Part I discusses the 17 IEGs discovered in 
this study induced by VEGF-A using suppression subtractive hybridization and 
differential screening techniques.  Study of RNA binding protein 5 (RBM5), the only 
IEG with an implicated role as a tumor suppressor gene and an apoptotic regulator is 
addressed in Part II of this dissertation.  Conclusions and future studies are discussed 
in Part III.  A protocol for production of full-length RBM5 in insect cells for RNA 




Another aspect this dissertation attempts to address is the resolution of signal 
transduction mediators upstream of RBM5 emerging from the VEGF/VEGFR signal 













Endothelial cells are usually quiescent unless stimulated by an angiogenic 
growth factor.  As discussed in Chapter 1, VEGF-A (VEGF165) plays a key role in 
angiogenesis since it not only acts as a specific mitogen of endothelial cells, but also 
is the most potent regulator of vascular permeability.  Much of the effort has been 
focused on the characterization of the signal transduction cascade emerging from the 
two receptors VEGFR1 and VEGFR2, resulting from VEGF-A stimulation.  At the 
beginning of this study, even though the entire signal transduction cascade emerging 
from the two receptors had been elucidated, there was scant information regarding the 
immediate early genes induced in endothelial cells through either of these receptors. 
The induction of immediate early genes (IEGs) represents the first wave of 
cellular response to external stimuli and does not require de novo protein synthesis.  
This rapid and transient response of immediate early genes consequently orchestrates 
the downstream genomic response, which is unique for each stimuli or cell type.  The 
immediate early gene response thus plays a critical role in translating diverse 
situations such as exposure to growth factors, stress or oxygen deprivation to a 




Edwards and Mahadevan, 1992).  Only a few immediate early gene products induced 
by VEGF-A stimulation have been discovered so far.  Some of the IEGs induced by 
VEGF cited in the literature are –CTGF, CYR61, COX2 and EGR1 (Babic et al., 
1998; Suzuma et al., 2000, Abe and Sato, 2001; Sato, 2001b). 
Although transcription factors belonging to NF-κB, Myc and AP-1 families 
such as c-Fos and c-Jun are most well known among the immediate early gene 
products, all IEGs are not transcription factors.  More than 100 different immediate 
early gene products have been identified so far.  The activation of a diverse set IEGs 
of which only a small subset may be overlapping as seen in different situations offer 
plasticity to the cells to respond to a variety of cell stimuli (Bravo, 1990).  The level 
of IEGs in quiescent cells is very low, but is induced rapidly within 0.5 to 2 hours of 
cell stimulus.  The IEGs are induced at the level of transcription and have a high 
turnover rate as expected since most of the immediate early gene products are 
responsible for the transition of cells from G0 to the G1 phase.  Immediate early gene 
expression is further augmented in the presence of protein synthesis inhibitors such as 
cycloheximide and anisomycin along with mitogen, leading to an over accumulation 
of IEG transcripts (Efrat and Kaempfer, 1984; Greenberg et al., 1986; Lau and 
Nathans, 1986).  This phenomenon known as ‘superinduction’ was first observed by 
Cochran et al. in 1983.  They observed induction of two genes KC and JE within 1 
hour of PDGF stimulation in presence of protein synthesis inhibitors in 3T3 cells. 
Based on different studies it is proposed that superinduction may be due to a 
four prong effect elicited by protein synthesis inhibitors (Edwards and Mahadevan, 




This increased mRNA stability may in turn be governed by three effects: 1) 
degradation of labile mRNAases or, 2) inhibition of translation which is needed for 
maintaining the rapid mRNA turnover kinetics and 3) auto-repression mechanism 
exhibited by some transcription factors or lastly, the presence of protein synthesis 
inhibitors may lead to entrapment of mRNAs on polysomes thus shielding them from 
cytosolic ribonucleases (Cochran et al., 1983; Wilson and Treisman, 1988; Pontecorvi 
et al., 1988; Edwards and Mahadevan, 1992). Secondly, protein synthesis inhibitors 
such as cycloheximide or anisomysin by themselves can stimulate nuclear signaling 
leading to phosphorylation of pp33 and pp15 chromatin associated proteins 
(Mahadevan and Edwards, 1991).  The third factor leading to superinduction may be 
due to loss of labile transcriptional repressors as suggested by Wall et al., in 1986 and 
Subramaniam et al., in 1989.  Lastly, there is increased transcription in presence of 
protein synthesis inhibitors suggesting that protein synthesis is essential to shut off 
translation (Greenberg et al., 1986; Edwards and Mahadevan, 1992). 
To derive a transcriptional set of IEGs unique to endothelial cells as a result of 
VEGF-A stimulation, the phenomenon of superinduction (to enrich IEG transcripts) 
along with suppression subtractive hybridization to exclusively select induced IEGs 
from other transcripts was used.  Suppression subtractive hybridization (SSH) to 
generate cDNA libraries was first described by Diatchenko et al. in 1999.  This 
technique relies upon a normalization step coupled with a subtraction step, resulting 
in the detection of even low copy number differentially expressed genes.  Using this 




each gene identified in this unique subset may be responsible for a significant part of 
the molecular signaling pathways leading to VEGF-A mediated angiogenesis. 
 
 
MATERIALS AND METHODS 
 
Cell culture and VEGF treatment 
Pooled HUVEC cells (Cambrex Biosciences) between passage 4 and 5 were 
grown to 80-90% confluence in EGM (Appendix B) supplemented with 1 ng/ml basic 
fibroblast growth factor (Invitrogen) at 37°C in a 5% CO2 incubator.  Prior to VEGF-
A stimulation, the cells were washed twice with 10 ml of EBM 0.5 (Appendix B) and 
consequently serum starved in 30 ml of EBM 0.5 for 18 hours.  Subsequent to serum 
starvation the cells were treated with 10 ng/ml of VEGF-A and or 10 μg/ml of 
cycloheximide (CHX) for 0, 1 and 3 hrs.  After growth factor stimulation, the cells 
were either harvested using ice cold 1 mM EDTA in phosphate buffered saline for 
replating or processed further for RNA isolation as mentioned below. 
 
RNA isolation 
HUVEC cells grown on 150 mm dishes (Corning) were stimulated with 
VEGF-A (10 ng/ml) for 0, 1 and 3 hours as stated in the above section.  For RNA 
isolation, the cells were lysed directly on the plate using 3 ml of RNA Bee (Tel-Test) 
per dish (Chomczynski and Sacchi, 1987; Sambrook et al., 1989).  RNA was further 




was added and mixed by shaking the tube vigorously for 15 seconds.  The tubes were 
incubated on ice for 5 minutes and further centrifuged for 15 minutes at 4ºC at 
12,000g for phase separation.  The upper clear aqueous phase was separated from the 
lower blue colored phenol phase and mixed with equal volumes of isopropanol.  RNA 
was precipitated by centrifuging the tubes at 7,500g for 5 minutes.  The RNA pellet 
was further washed in 2 ml of 75% ethanol and dissolved in either DEPC treated 
distilled water or TE buffer (Appendix B).  RNA integrity was confirmed by 
measuring 260/280 absorbance ratio and by running a 5 µl aliquot on 1.2% 
formaldehyde agarose gel. 
 
Construction of suppression subtractive hybridization cDNA library 
A suppression subtractive hybridization (SSH) library was screened to 
identify differentially expressed genes in endothelial cells as a result of stimulation by 
VEGF-A (VEGF165).  The library had been constructed by Dr. Brown in our lab using 
PCR Select TM cDNA Subtraction Kit according to the manufacturer’s instructions 
(Clontech Laboratories).  Briefly, polyA+ RNA was isolated using Oligotex kit 
(Qiagen) for subsequent cDNA preparation from HUVEC cells treated with 10 ng/ml 
VEGF-A and 10 μg/ml cycloheximide for 3 hours (‘tester’ cDNA pool) and untreated 
HUVEC cells (‘driver’ cDNA pool).  Hybridization of excess driver cDNA to the 
tester cDNA pool resulted in a subtracted library of cDNAs potentially enriched in 






Differential screening of suppression subtractive hybridization cDNA library 
Selection of recombinant clones - The subtracted transcripts (refer to the 
above section) were ligated into Sma1 digested pGEM®-3Zf(+) vector (Promega).  
Following transformation in DH5α cells (Promega), the cells were plated onto Luria-
Bertani (LB) agar plates containing 100 µg/ml ampicillin, 80µg/ml X-gal (5-bromo-
4-chloro-3-indolyl-beta-D-galactopyranoside) and 0.5mM IPTG (isopropyl-β-D-
thiogalactopyranoside).  After overnight incubation at 37°C the recombinant white 
colonies were identified by the blue/white screening and picked up randomly.  Each 
selected recombinant colony was grown separately overnight at 37°C/200 rpm in 3 ml 
of LB broth containing 100 μg/ml of ampicillin.  Plasmid DNA was isolated from 
each of the clones by performing boiling plasmid minipreps (Sambrook et al., 1989). 
Preparation of dot blots - Each plasmid clone was mixed with equal amounts 
of 0.6N NaOH (9 µl each) and arrayed (dot blotted) in triplicates onto individual 
GeneScreen Plus® nylon membrane (NEN™ Life Science).  The blots were air dried 
and subsequently neutralized in 0.5M Tris HCl (pH 7.5).  After rinsing the blots 
thrice in distilled water, the plasmid DNA was crosslinked to the nylon membranes 
by a 15 second exposure to ultraviolet light. 
Preparation of radiolabeled probe - Equal quantities (75 ng) of ‘tester’ and 
‘driver’ cDNA were labeled in two separate reactions using Prime-a-Gene® Labeling 
System (Promega) according to manufacturer’s directions.  Briefly, the each cDNA 
pool dissolved in 4µl of TE was mixed with 10 µl of 5X labeling buffer (containing 




mixture was boiled for 5 minutes and cooled on ice.  Each reaction was then 
assembled by adding the following components: 
dNTPs (20 µM each of dGTP, dATP and dTTP)   2µl 
BSA        2 µl 
[α-32P] dCTP (10 µCi/µl or 3,000 Ci/mmol)    5 µl 
DNA Polymerase I, Large Klenow Fragment (5 u/µl)  1 µl 
The labeling reactions were incubated further for 90 minutes at room temperature.  
The labeled cDNA (tester and driver pool) was precipitated by adding 0.2M EDTA (5 
µl), 10M ammonium acetate (18 µl) and of ethanol (150 µl) on ice for 2 hours.  The 
reaction was then centrifuged for 15 minutes and the pellet redissolved in 50 µl of TE 
buffer.  An aliquot (1 µl) of each labeled tester and driver cDNA pool was further 
assayed for the amount of radioactivity incorporated by liquid scintillation.  The 
labeled tester and driver cDNA (equal counts) were then boiled for 5 minutes with 
500 µl of FSS and added to the blots which were processed as detailed in the next 
section.  Approximately 50 ng of ‘cocktail’ containing cDNAs representing all the 
genes identified before from this library, was also labeled in a similar fashion and 
used to hybridize the third blot. 
Membrane hybridization - The dot blots were pre-hybridized at 42ºC for 4 
hours in 10 ml of 1:1 FSS:pre-hybridization (Appendix B) solution.  After pre-
hybridization the solution was replaced with 10 ml of 1:1 FSS:hybridization solution 
(Appendix B).  The labeled probes were added to the individual blots and further 




Washing protocol and exposure - After hybridization each of the three blots 
were washed as follows before exposing to phosphor screen (BioRad) for 
autoradiography: 
100 ml 1X SSC/0.1%SDS for 10 minutes at room temperature 
100 ml 0.2X SSC/0.1% SDS for 30 minutes at 42ºC X 3 times 
The phosphor screen was scanned using Molecular Imager FX (BioRad) and images 
were processed using Quantity One software (BioRad). 
Differential Screening - All autoradiography images were further processed 
with Adobe Photoshop software.  All clones having at least twice the signal intensity 
on the tester cDNA probed blot as compared to the driver cDNA probed blot and 
none on the cocktail were selected.  The selected clones representing potentially 
VEGF-A induced IEGs were handled as detailed below. 
 
Isolation of inserts corresponding to IEGs potentially induced by VEGF-A 
Plasmid preps - Each of the plasmid clones identified as potentially positive 
was selected and grown overnight in 100 ml of Terrific broth containing 100 µg/ml 
ampicillin at 37°C/200 rpm.  Plasmid DNA was isolated by the alkaline lysis method 
(Sambrook et al., 1989).  Purity of the isolated DNA was confirmed by measuring 
260/280 absorbance ratio and by running 2 µg on 1% agarose gel. 
Restriction digests of plasmids to isolate inserts - Two restriction enzymes 
pairs (EcoR I - Hind III and Sac I - BamH I), each corresponding to the T7 and SP6 
MCS of pGEM®-3Zf(+) vector were used to splice out the inserts from each of the 




then run on a 1% agarose gel.  The enzyme pair giving the largest insert size was 
selected for each plasmid clone and the reaction was scaled up to yield 2 µg for each 
insert.  The scaled up restriction digests were run in a 1% agarose gel and the inserts 
were purified using DEAE membrane and high salt solution extraction method 
(Sambrook et al., 1989). 
Sequencing - All inserts isolated above were sequenced by the dye terminator 
sequencing method at our campus facility.  BLAST search analysis was carried out to 
identify the IEGs.  Up-regulation of some of the IEGs by VEGF-A was confirmed by 
Northern analysis as given below. 
 
Northern analysis 
Preparation of RNA samples - Total RNA (10-15 µg/well) dissolved in 
formamide in a final volume of 20 µl was mixed with 7 µl of formaldehyde, 4 µl of 
5X formaldehyde RNA gel running buffer and 9 µl of DEPC treated distilled water in 
a microcentrifuge tube.  The RNA was denatured by heating the samples to 65ºC for 
10 minutes and then chilled on ice.  Subsequently, 4 µl of RNA gel loading buffer 
along with 2 µl of 10 mg/ml ethidium bromide was added per 40 µl of the RNA 
samples.  The RNA samples were loaded onto a pre-run 1.2% formaldehyde agarose 
gel and separated by electrophoresis at 90 volts (constant voltage) until the 
bromophenol blue dye migrated to the bottom 2/3rd of the gel.  The gel was soaked in 
150 ml distilled water twice for 15 minutes and in 150 ml 10X SSC for 30 minutes to 
remove all the formaldehyde.  The RNA bands were seen by ultraviolet illumination 




Transfer of RNA to nylon membranes - The RNA from gel was transferred 
overnight to a GeneScreen Plus® nylon membrane (NEN™ Life Science) using 
capillary elution in an ascending flow of 10X SSC buffer (Sambrook et al., 1989).  
The nylon membrane was pried away from the gel and washed in 150 ml of 2X SSC 
for 10 minutes to remove any gel particles sticking to the membrane.  The damp 
nylon membrane was then exposed to ultraviolet illumination for 15 seconds to 
crosslink the RNA and then dried under vacuum in between 2 sheets of 3MM paper at 
80ºC for 2 hours. 
Preparation of radiolabeled probe and membrane hybridization - Linear 
insert DNA (50 to 100 ng) labeled using Prime-a-Gene® Labeling System (Promega) 
was hybridized to RNA blots as detailed in the previous section. 
Washing protocol and exposure - After hybridization the blots were washed as 
follows before exposing to phosphor screen (BioRad) for autoradiography: 
100 ml 1X SSC/0.1%SDS for 10 minutes at room temperature 
100 ml 0.1X SSC/0.1% SDS for 30 minutes at room temperature X2 
100 ml 0.1X SSC/0.1% SDS for 30 minutes at 42ºC 
The phosphor screen was scanned using Molecular Imager FX (BioRad) and images 









RESULTS AND DISCUSSION 
 
Differential screening of cDNA library 
Differential screening of 329 clones led to the identification of 21 new clones 
representing putative immediate early genes induced by VEGF-A (figure 8).  
Subsequent sequencing and BLAST search identified a new putative VEGF-A 
response gene set of 14 new genes (table 3) along with ZNEU1, IL-8 and RBM5 
which were previously identified in our lab by Dr. Brown (Altschul et al., 1997).  
Interestingly, all of the inserts represented the 3' end of the identified genes and 
ranged from 200-500 base pairs in length. 
Additionally, to root out any false positives, induction of IEGs was confirmed 
by Northern analysis using RNA isolated from endothelial cells stimulated with 
VEGF-A only (in the absence of cycloheximide).  The probes used for Northern 
analysis were the same inserts sequenced to identify the genes as explained above.  
Up-regulation of all immediate early genes verified by Northern analysis were 
induced within 1 hour of VEGF-A stimulation and tapered off by the 3 hours time 
point.  Equal loading of RNA for each time point was confirmed by gel analysis or by 
striping and re-probing the blots with GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) housekeeping gene.  Up-regulation by VEGF-A could not be 
confirmed for EXOC4, DDIT3, MIDN, RGS3 and clone 648 due to lack of good 
probes for Northern analysis.  Of all the positive clones analyzed it was found that 









Figure 8:  An autoradiograph showing differential screening of a cDNA library made 
by suppression subtractive hybridization method to isolate immediate early genes 
induced by VEGF-A in human umbilical vein endothelial cells.  The dot blots 
represent 172 of the 329 clones arrayed in duplicates on A) forward probe hybridized 
and B) reverse probe hybridized blots.  Both the membranes were probed with equal 
counts of [α-32P] dCTP radioactivity as determined by liquid scintillation.  Plasmid 
clones showing at least twice the signal on forward probe blot-A than on a reverse 
probed blot-B and on the cocktail probe blot (not shown) were selected and processed 
further as outlined in Materials and Methods section.  This selection process was 
designed to eliminate repetitive selection of the cDNAs representing genes previously 










Table 3:  List of immediate early genes identified by differential screening of the 
cDNA library created by suppression subtractive hybridization.  Most of the genes 
identified in this new putative VEGF-A response gene set have been confirmed to be 
induced either by Northern analysis in this study or have been cited in the literature. 








  1. ATF3 YES 1q32.3 467 Activating transcription factor 3, transcriptional repressor 
  2. DDIT3 N/A 12q13.1 1649 
DNA-damage-inducible 
transcript 3 encoding a bZip 
protein 
  3 EGR2 YES 10q21.1 1959 
Early growth response 2, 
Cys2His2 zinc finger 
transcription factor 
  4. FOSB/ GOS3 YES 19q13.32 2354 
Leucine zipper /G0/G1 switch 
regulatory gene 3 protein 
  5. PTGS2/ COX-2 YES 1q25.2 5743 
Prostaglandin-endoperoxide 
synthase or cyclooxygenase 2 
  6. CTGF YES 6q23.1 1490 Connective tissue growth factor 
  7. DUSP1/ CL100 YES 5q34 1843 Dual specificity phosphatase 1 
  8. EXOC4 N/A 7q31 60412 Exocyst complex 4 or SEC8 protein 
  9. RGS3/ RGP3 N/A 9q32 5998 
Regulator of G protein 
signaling 3, a GTPase 
activating protein for g(ialpha) 
and g(qalpha) 
10. MIDN N/A 19p13.3 90007 Midnolin (midbrain nucleolar protein) 
11. Clone 532 YES 12 AC009246 Homo sapiens DKFZp686D0473 cDNA 
12. Clone 648 N/A 1p36.12 AK027830 Homo sapiens, highly similar to GENE 33 polypeptide 
13. FOS YES 14q24.3 AF111167 Leucine zipper /jun dimerization protein 
14. IER2/ ETR101 YES 19p13.13 9592 
Immediate early response 2 
(transcription factor) 
15. ZNEU1/  EGFL7 YES 9q34.3 353156 Vascular endothelial –statin 
16. IL8 YES 4q13-q21 3576 Interleukin 8, CXC chemokine 
17. RBM5/ LUCA15 YES 3p21.3 10181 
Putative tumor suppressor gene 





























Figure 9:  Representative Northern analysis blots (A-F) showing induction of some of 
the immediate early genes in endothelial cells stimulated with VEGF-A in absence of 
cycloheximide.  Northern analysis was performed to rule out any false positives 
identified by the differential screening of cDNA library created by suppression 
subtractive hybridization.  The identified IEGs are induced within 1 hour of VEGF-A 
stimulation and return to basal levels within 3 hours.  Equal loading of total RNA was 
confirmed by gel analysis showing 28S and 18S rRNA bands (A-E) or by striping and 
re-probing the blots with a housekeeping gene GAPDH (F).  Densitometry analysis 
showed approximately 2.5 fold up-regulation of RBM5 as compared to GAPDH. 
0         1       3 hrs 
A) Clone 532 B) EGR1 
C) IL8 D) CTGF 
E) ATF3 F) RBM5 and GAPDH 
0         1       3 hrs 0         1       3 hrs 0         1       3 hrs 
0         1       3 hrs 0         1       3 hrs 0         1       3 hrs 0         1       3 hrs 






Immediate early genes induced by VEGF in endothelial cells 
While this project was at its beginning, a cDNA microarray (7267 genes) 
study to identify global expression as a result of VEGF-A stimulation in endothelial 
cells (HUVEC) was conducted by Abe and Sato in 2001.  However, there was very 
little overlap in the genes identified as induced by VEGF-A in this study and the 
cDNA microarray study conducted by Abe and Sato.  This discrepancy may be 
possible due to several reasons such as lack of specificity of cDNA microarray 
probes, different experimental settings or that some of the known and novel genes 
identified in this study were not represented by the 7267 clones in the microarray 
study (Kothapalli et al., 2002).  The only overlapping genes identified as induced in 
both the studies were EGR2 and COX2.  Although an in depth discussion of each IEG 
identified is beyond the scope of this chapter, a brief overview of each IEG class 
based on their function and their significance in angiogenesis is presented below. 
Transcription factors - In this study, six transcription factors formed a major 
component of the 17 IEGs induced by VEGF-A in endothelial cells.  So far only three 
transcription factors identified in this study, EGR2, FOS and FOSB have been cited 
in the literature as being induced by VEGF-A.  Induction of the FOS gene is not very 
surprising since its induction has been shown to be most promiscuous in various 
studies and is known to be widely induced during stress responses, exposure of cells 
to mitogens and hormones (Greenberg and Ziff, 1984; Kruijer et al., 1984; Mitchell et 
al., 1985; Sassone-Corsi, 1994).  Like FOS many of the VEGF-A inducible IEGs 
such as, EGR2, and CYR61 have the SRE (serum response element) in their 




in its promoter which governs its induction as a response to stimulators of adenylyl 
cyclase pathway and changes calcium concentration (Sassone-Corsi et al., 1988).  
Members of the FOS gene family (FOS, FOSB, FOSL1 and FOSL2) are all leucine 
zipper proteins capable of heterodimerizing with JUN family of proteins, forming the 
AP-1 transcription factor complexes which govern cell differentiation, proliferation 
and other biological processes (Angel and Karin, 1991).  Induction of FOSB gene and 
its dominant negative alternatively spliced counterpart ΔFOSB by VEGF and PlGF 
(placental growth factor) a member of VEGF growth factor family, which selectively 
activates through the VEGFR1 or Flt-1 receptor has been recently confirmed by 
Holmes and Zachary in 2004. 
Early growth response gene 2 (EGR2) containing three tandem C2H2 type 
zinc fingers was first discovered by Joseph et al. in 1988 by using a mouse EGR1 to 
probe a cDNA library coupled with low stringency washes.  Microarray analysis by 
Matsushima-Nishiu et al. in 2001 revealed a 2.5 fold induction of EGR2 by PTEN a 
tumor suppressor gene encoding a phosphatase, which downregulates the 
phosphatidylinositol-3-kinase pathway.  It is now known that EGR2 mediates PTEN 
induced apoptosis in various cancer cell lines by inducing pro-apoptotic BNIP3L and 
BAK (Unoki and Nakamura, 2003).  Other than this study, induction of EGR2 (3.2 
and 1.1 fold in 0.5 and 2 hours respectively) by VEGF was also reported by Abe and 
Sato.  However, the relevance of EGR2 induction in angiogenesis is not known. 
Immediate early response 2 (IER2/ETR101/pip92) was first discovered by 
Charles et al. in 1990 as an IEG induced by serum growth factors and TPA (12-O-




demonstrated as a response to activation of muscarinic acetylcholine receptors and by 
human T-cell leukemia virus type I Tax oncoprotein (von der Kammer et al., 2001; 
Chen et al., 2003).  Although, IER2 has also been implicated to control apoptosis in 
primary neurons, the physiological function of this IEG is still unknown (Schneider et 
al., 2004). 
Activating transcription factor 3 (ATF3) homodimer is a transcriptional 
repressor rather than an activator of promoters containing ATF/CRE elements.  ATF3 
is a 22 kDa basic leucine zipper protein (bZip) and is classified under ATF/CREB 
(cAMP responsive element binding) family of transcription factors (Hai et al., 1999).  
All proteins classified under the ATF/CREB family are capable of forming 
heterodimers with each other and also with other bZip proteins of the AP-1 and 
C/EBP (CCAAT/enhancer-binding protein) family.  Although, ATF3 homodimer acts 
as a transcriptional repressor, it is now known that ATF3 heterodimers with JUN-D 
(c-jun) acts as a transcriptional activator (Hai and Hartman, 2001).  Other bZip 
proteins capable of forming heterodimers with ATF3 include JUN-B, ATF2 and 
DDIT3/GADD153, one of the IEGs identified in this study.  ATF3 is induced by 
various stress signals such as hypoxia or by cytokines, cycloheximide, anisomycin or 
agents capable of inducing JNK/SAPK pathway in cultured cells (Hai et al., 1999; 
Cai et al., 2000; Hai and Hartman, 2001; Wek et al., 2006).  However, northern 
analysis has confirmed that induction of ATF3 is due to stimulation by VEGF-A and 
not due to adverse action of cycloheximide used to construct the cDNA library (this 
study).  Even though ATF3 was discovered in 1989 by Hai et al., its physiological 




p53 thereby stabilizing it and promoting its tumor suppressor activity (Yan and Boyd, 
2006). 
Similar to ATF3, DDIT3/CHOP (c/EBP homologueous protein) a bZip 
nuclear protein which dimerizes with C/EBP transcription factors is induced as a 
result of cellular stress (specifically endoplasmic reticulum) response (Ron and 
Habner, 1992; Oyadomari and Mori, 2004).  Overexpression of DDIT3 results in cell 
growth arrest and may also induce apoptosis by decreasing the level of Bcl-2 protein 
(Matsumoto et al., 1996; Oyadomari and Mori, 2004).  The DDIT3 protein under 
normal conditions is expressed at low levels in the cytosol, but undergoes 
phosphorylation mediated by p38 MAP kinase and is transported into the nucleus 
during cellular stress (Oyadomari and Mori, 2004). 
Growth factors – Connective tissue growth factor (CTGF) like VEGF, ATF3 
and DDIT3 is up-regulated under ischemia or low oxygen induced stress.  Up-
regulation of CTGF as a result of VEGF stimulation of endothelial cells has been 
confirmed in this study and by Suzuma et al in 2000.  CTGF (CCN2) is classified 
under the CCN family of cysteine-rich matricellular proteins which play an important 
role in mitosis, adhesion, extracellular matrix production, chondrogenesis, 
osteogenesis and angiogenesis (Brigstock, 2003; Leask and Abraham, 2003; Perbal, 
2004).  Both CTGF and CYR61 (CCN1) are significantly induced by VEGF and 
estrogen, and are considered as downstream targets of TGF-β (Abe and Sato, 2001; 
Brigstock, 2003; this study).  Similar to VEGF, CCN proteins are found associated 
with the heparan sulfate proteoglycans at the cell surface or in the extracellular matrix 




angiogenic factor by binding to VEGF.  This binding is abrogated by the selective 
digestion of CTGF by MMP-1, -3, -7 and -13 (matrix metalloproteinase) to release 
VEGF and recover its angiogenic potential (Hashimoto et al., 2003).  Thus, there are 
two controversial roles of CTGF suggested so far, both as an anti-angiogenic and a 
pro-angiogenic factor.  Future research defining its precise role in both physiological 
and pathological angiogenesis will indeed be exciting. 
Cytokines – IL8 was first discovered as a chemotactic factor for leukocytes.  
Pro-angiogenic activity of IL8/CXCL8 was first demonstrated by Koch et al. in 1992.  
They demonstrated that IL8 triggered chemotaxis and proliferation of HUVEC and 
also induced angiogenesis when injected in rat cornea (Koch et al., 1992).  Like 
VEGF, IL8 is also potently induced under hypoxic conditions (Papetti and Herman, 
2002; Mizukami et al., 2005).  Production of IL8 by endothelial cells in cutaneous 
inflammation and also by various tumors such as melanomas, non small cell lung 
carcinomas, colon and bladder cancer is well documented (Huang et al., 2002; 
Rosenkilde and Schwartz, 2004).  Treatment of melanoma cells in vitro by humanized 
ABX-IL8 antibodies suppressed metastasis of melanoma cells and also decreased the 
induction of MMP-2, a key enzyme involved in degradation of basement membranes 
(Huang et al., 2002; Papetti and Herman, 2002).  However, the induction of IL8 
directly by VEGF-A has not yet been documented.  IL8 was induced within 1 hour in 
endothelial cells stimulated with VEGF-A (figure 9). 
Enzymes – Two enzymes PTGS2/COX-2 (cyclooxygenase) and 
DUSP1/CL100 (dual specificity phosphatase) were among the 17 IEGs induced by 




endotoxins, mitogenic factors and is inhibited by glucocorticoid (Cheng et al., 2005; 
Wu et al., 2005).  The enzyme cyclooxygenase also known as prostaglandin-
endoperoxide synthase is localized in the inner surface of the endoplasmic reticulum 
and nuclear envelope and governs the two step process of converting arachidonic acid 
to hydroperoxy endoperoxide and then to hydroxy endoperoxide (PGH2) (Ristimaki, 
2004; Rouzer and Marnett, 2005; Wu et al., 2005).  PGH2 is further converted to 
active prostanoids PGI2 and PGE2.  Increased levels of COX-2 (via increased 
prostaglandin production) in tumors can confer a pro-angiogenic effect by increasing 
VEGF production, immunosuppression and by inhibiting endothelial cell apoptosis 
via increased production of Bcl-2 and Akt signaling (Gately and Li, 2004; Patrignani 
et al., 2005; Surh and Kundu, 2005).  The pro-angiogenic effects of COX-2 are 
reversed by COX-2 inhibitors and NSAIDS (non-steroidal anti-inflammatory drugs), 
thus making it a possible therapeutic target against cancer, chronic inflammatory 
diseases and retinopathies (Iniguez et al., 2003). 
Activation of the MAP kinase pathway is an essential part of many signal 
transduction cascades, translating the extracellular signal of mitogens or stress to a 
cellular response (Roux and Blenis, 2004).  Prolonged activation of MAP kinase 
results in transformation of fibroblast cells or may inhibit or activate apoptosis 
depending on the extracellular signal the kinase involved (Sánchez-Pérez, 2000).  
Thus, each MAP kinase is tightly regulated by phosphatases and dephosphorylation at 
even one amino acid (tyr/thr) results in the inactivation of kinase.  DUSP1/MKP1 
(dual specificity phosphatase-1/MAP kinase phosphatase-1) was discovered in 1992 




factors, oxidative and heat stress.  Usually the same set of signals governing the 
activation of MAP kinases also induce the respective phosphatases, thus representing 
a negative feed back loop to regulate the MAPK activity (Sohaskey and Ferrell, 
2002).  DUSP1 binds and inactivates ERK1/2, JNK and p38α isoforms (Slack et al., 
2001). 
Secreted factors/proteins –Induction of EGFL7/ZNeu1 (EGF-like domain, 
multiple 7) transcript by VEGF was first discovered in this study by Dr. Brown.  
Sequence analysis shows the presence of two EGF-like domains which can bind 
calcium along with a cysteine rich cluster capable of forming disulfide bonds.  
However, function of this protein was not known until 2003, when Soncin et al. 
demonstrated that ZNeu1 is secreted by endothelial cells and can inhibit migration of 
smooth muscle cells.  ZNeu1 has no effect on proliferation of smooth muscle cells, 
unlike TGF-β and PTEN which affect both migration and proliferation.  Based on this 
function they named this protein VE-statin (vascular endothelial statin).  Localization 
of VE-statin in endoplasmic reticulum has been confirmed in our lab by Dr. Brown 
and by Soncin et al.  EGFL7 transcripts are expressed on day 7.5 of embryonic 
development, slightly behind the flk-1 transcripts, the earliest marker for endothelial 
cell differentiation in uncommitted embryonic mesoderm.  EGFL7 expression 
parallels with the expression of tie-2 and VE-cadherin endothelial markers (Sato et 
al., 1993; Shalaby et al., 1995; Soncin et al., 2003).  Loss of function analysis of 
Egfl7 in zebra fish implies its crucial role in formation of vascular tubes or 
tubulogenesis, a key step in which vascular cords form vessels with a central lumen 




in embryonic development, both the downstream targets and its precise role in 
angiogenesis is unknown. 
Secretory/Exocytosis pathway - Exocyst 4 (EXOC4/SEC8) was first 
discovered in S. cerevisiae by Novick and Schekman in 1979 as one of the 10 SEC 
proteins responsible for regulating vesicular traffic from the Golgi to the plasma 
membrane.  Bowser et al. in 1992 cloned SEC8 and concluded it to be an essential 
gene along with SEC15 for exocytosis in yeast.  Recent evidence shows that the 
mammalian sec6/8 complex is essential for docking vesicles to specific sites on 
plasma membrane (Hsu et al., 1999).  Sec6/8 complex is found both on the trans-
Golgi network and at the plasma membrane cell-cell contact sites where it is involved 
in polarization of epithelial cells (Yeaman et al., 2001; Yeaman et al., 2003).  
Unfortunately, induction of SEC8 by Northern analysis could not be confirmed in this 
study. 
Regulator of G-protein signaling – RGS3 (Regulator of G-protein signaling 3) 
is one of the more than 20 proteins in the RGS gene family discovered so far.  RGS 
proteins can modulate the function of both activated GPCRs (G protein receptors) 
(Riddle et al., 2005; Abramow-Newerly et al., 2006).  These proteins were initially 
identified as GAPs (GTPase activating proteins) capable of increasing the intrinsic 
GTPase activity of Gα subunit of heterotrimeric G proteins.  But recent findings 
suggest that their role is much more complicated than previously thought.  RGS3 was 
first discovered in 1996 by Druey et al. as a human homologue of yeast SST2 protein, 
which downregulates the MAP kinase signaling pathway induced through a 




the GPCRs activated by chemoattractants SDF-1 (Lu et al., 2001).  Bidirectional 
signaling by ephrin B and ephrin B receptors govern key physiological processes such 
as axon guidance and blood vessel formation (Chapter1, Part I).  Given the important 
role played by RGS3 in modulation of Ca2+ dependent Gαq/11 linked muscarinic M3 
and gonadotropin-releasing hormone receptor, ephrin B signaling and inhibition of 
Gαs-stimulated adenylyl cyclase activation, its role in VEGF mediated angiogenesis 
is unknown (Tovey and Willars, 2004; Jaen and Doupnik, 2005; Abramow-Newerly 
et al., 2006).  Induction of RGS3 by VEGF-A was not confirmed by northern analysis 
in this study due to lack of a good probe. 
Tumor Suppressor Genes – RNA binding motif protein 5 (RBM5) was the 
only tumor suppressor gene discovered in this study as inducible by VEGF-A.  
Induction of a tumor suppressor gene by VEGF-A has not been reported in any of the 
studies designed to discern global expression patterns induced by VEGF (Abe and 
Sato, 2001).  Thus, this was a not only an intriguing but an exciting avenue of 
research that I decided to pursue as my dissertation topic.  Moreover, the fact that the 
function of this multi-modular gene was as yet unknown presented an opportunity to 
design multiple projects to discern the structure and function relationships of RBM5.  
An in depth discussion of RBM5 is presented in the next section of this dissertation 
(Chapter 1, Part II). 
Other immediate early genes – MIDN, clones 532 and 648 are discussed in 
this section since their function is not yet known.  Midnolin (MIDN/midbrain 
nucleolar protein) gene was first cloned by Tsukahara et al. in 2000 from mouse 




12.5.  It is implicated that MIDN localized in the nucleolus plays a role in regulation 
of genes involved in neurogenesis (Tsukahara et al., 2000).  The probable human 
ortholog of mouse MIDN is present on chromosome 19p13.3. 
DKFZp686D0473, a 3.3 kilobase cDNA isolated from human endometrium 
cancer cell line corresponds to insert isolated from clone 532 (Altschul et al., 1997).  
Northern analysis using clone 532 insert demonstrates the induction of two transcripts 
with molecular weights of approximately 6.5 and 3.5 kilobases during both 1 and 3 
hours time points of VEGF-A stimulation (figure 9).  BLAST search analysis of 
sequence corresponding to clone 648 reveals that it may correspond to GENE 33 
polypeptide located on chromosome 1p36.12 (Altschul et al., 1997).  Although 
domain search carried out by InterProScan shows the presence of two transmembrane 
domains and a signal peptide, there is no known molecular function for this gene at 





As a step towards defining the mechanism of VEGF-A action on endothelial 
cells I focused on identifying the immediate early genes induced by VEGF-A, a 
hitherto uncharted research area.  Using differential screening of a cDNA library 
created by suppression subtractive hybridization technique I identified 17 immediate 
early genes up-regulated by the mitogenic stimulation of VEGF-A in the normally 




identified in this study was further confirmed by Northern analysis thus, proving the 
efficacy of this powerful technique.  Transcription factors such as FOS, ATF3, 
DDIT3 and EGR2 constituted a major portion of the 17 different IEGs identified in 
this study.  Surprisingly, immediate early genes with varying functions such as, 
secreted factors, growth factors, cytokines and novel genes were also rapidly induced 
by VEGF-A.  Undoubtedly, identification of 17 IEGs in this unique VEGF-A 
response gene set opened up numerous exciting avenues for further research, each 
possibly leading to a more clear understanding of the pleiotropic effects manifested 
by VEGF-A in endothelial cells.  Among these 17 IEGs, I decided to focus on RBM5 
(RNA binding motif protein 5), the only VEGF-A inducible tumor suppressor gene 
identified so far, whose role in angiogenesis if any seemed paradoxical.  The second 
part of my dissertation summarizes research done on RBM5 (Chapter 1, Part II) and 













As mentioned in Part I Chapter 2, RBM5 was identified as one of the 17 
immediate early genes induced in endothelial cells stimulated by VEGF-A.  RBM5 
represents an exciting finding since it is the only putative tumor suppressor gene 
(TSG) identified in this unique immediate early gene set comprising of many 
transcription factors and growth factors among others.  This chapter summarizes the 
findings on RBM5 including its discovery, role as a tumor suppressor gene and 
structure and function relationships.  When I started working on this project, the role 
of RBM5 as a regulator of apoptosis had been discovered by Sutherland et al. in 2000 
and since has also been reported by Oh et al. in 2006. 
 
 
DISCOVERY OF RBM5 
 
RBM5 along with RBM6 was one of the genes identified on chromosome 




region was frequently deleted in malignancies of head, neck, gastrointestinal, breast, 
in addition to vestibular schwannomas, renal cell and small cell lung carcinomas 
(SCLC) (Naylor et al., 1986; van der Berg et al., 1996; Kok et al., 1997; Timmer et 
al., 1999a).  Allelotyping, LOH (loss of heterozygosity) and overlapping homozygous 
deletion analyses in three SCLC cell lines NIH-H1450, NIH-H740 and GLC20 
pinpointed a 370 kilobase region corresponding to the chromosomal locus 3p21.3 as a 
region most likely to harbor TSGs (Wei et al., 1996).  This region was first cloned 
and mapped as a 600 kilobase contig in 1996 by Wei et al. in an attempt to discover 
putative tumor suppressor genes present at this region.  Drabkin et al. and Timmer et 
al. in 1999 simultaneously reported presence of LUCA15 (lung cancer 15) and 





Sequence comparison of RBM5 using HomoloGene (National Center for 
Biotechnology Institute website) shows that it is evolutionary conserved across the 
species with homologues found in rat (98.3%), mouse (89.9%), Drosophila (35.1%), 
Arabidopsis (33.1%) and zebrafish (99.6%).  A cartoon representing taxonomic tree 
constructed using the SMART software demonstrates this in figure 10 (Shultz et al., 
1998; Letunic et al., 2006).  RBM5 shares a 51% homology with RBM10 
(DXS8237E) located on Xp11.23 and a 30% homology with RBM6 present on the 




Another gene UBE1L present on chromosome 3p21 is homologous to UBE1 on the X 
chromosome next to RBM10.  The orientation between RBM10 and UBE1 on X 
chromosome and RBM6, RBM5 along with UBE1L on chromosome 3 is inverted 
(figure 11).  RBM6 is closely related to RBM5 in terms of exon structure with over 
nine exons sharing more than 25% homology (Timmer et al., 1999a).  Thus, these 
data suggests that there has been a rearrangement of chromosome Xp11 (3-23) in 3p 
21.3 region at some point in evolution (Timmer et al., 1999b).  The region Xp11.3-














Figure 10:  A model constructed using the SMART (Simple Modular Architecture 
Research Tool) software demonstrating the presence of proteins homologous to 
RBM5 across the species, in eukaryotes – rat, mouse, chicken and also in plants – 
Arabidopsis.  Even though there is negligible presence of homologous proteins in 
Archae, proteins sharing almost 100% similarity with RBM5 exist throughout 
eukaryota suggesting its evolutionary significance.  The SMART program is provided 
























Figure 11:  Chromosomal location of RBM5 with respect to RBM6 and UBE1L on 
chromosome 3p21.3.  Part A shows the gene arrangement of an RBM5 homologue 
RBM10 (DXS8237E) with respect to UBE1 on chromosome Xp11.3-11.23.  
Comparison of chromosomal regions Xp11.3-11.23 (A) and 3p21.3 (B) suggests that 
there was an inverse genetic rearrangement of Xp11.3-11.23 region during evolution.  
RBM6 which is present on the telomeric end shares a greater similarity with RBM5 
than with RBM10, indicating that RBM6 resulted from gene duplication of RBM5.  
The numbers below indicated the distance between the genes in kilobases.  Both the 
regions 3p21.3 and Xp11.3-11.23 are known hotspots for various cancers and 









The 2448 basepair RBM5 coding sequence is made up of 25 exons ranging 
from 61 basepairs (exon 8) to 627 basepairs (exon 25) and codes for a 815 amino acid 
protein with a molecular weight of 120 kDa (Timmer et al., 1999b; Sutherland et al., 
2000; this study).  The annotated sequence of 3135 basepairs RBM5 mRNA depicting 
exon boundaries and SNP as provided by Ensembl Transcript report available at 
EMBL (European Molecular Biology Library) is shown in figure 12.  Sequence 
analysis using PROSITE, PSORT and SMART programs reveal multiple domains 
present in the full-length RBM5 protein (Bairoch, 1991; Schultz et al., 1998; Nakai 
and Horton, 1999).  The various domains along with their amino acid positions are 
given below. 
 
Domains Amino acid positions 
Exon 
number 
BIPARTITE NLS [RRDSDYKRSSDDRRGDR] 34-50 3 
RRM1/RNP1 (OCTAMER) [RGFAFVEF] 140-147 6 
ZnF1 (ZnF type C4) [C(x2)C(x10)C(x2)C] 181-210 7-8 
RRM2/RNP1 (OCTAMER) [RGFAFVQL] 274-281 10 
GLUTAMINE RICH REGION 362-385 13-14 
OCTAMER REPEAT/OCRE DOMAIN 452-511 17-18 
KEKE MOTIF 523-535 19 
AMPHIPATHIC HELIX 536-553 19 
COILED COIL 614-648 21 
ZnF2 (ZnF TYPE C2H2) [C(x2)C(x12)H(x6)H] 647-677 21 
COILED COIL 672-711 21-23 
BIPARTITE NLS [RREKYGIPEPPEPKRKK] 708-724 23 
GLYCINE RICH REGION (G PATCH DOMAIN) 743-789 25 
 
Table 4:  Various domains and their respective positions in the full-length 815 amino 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































As the name suggests RBM5 has two RRM (RNA-recognition motif) domains 
RRM1 (98-178) and RRM2 (231-315).  Each RRM domain comprises two conserved 
sequence motifs, an octapeptide (RNP1) and a hexapeptide (RNP2) embedded within a 
highly variable sequence of approximately 80-100 amino acids.  The structure of RRM 
domain is βαββαβ, with the conserved octamer and hexamer sequences present in the β-
sheets.  Both RNP1 and RNP2 domains can function in RNA binding.  However, the 
specificity of RNA bound is determined by the amino acid residues surrounding the RNP 
domains (Burd and Dreyfuss, 1994).  The RNP2 domains (hexapeptide) of RBM5 are 
less conserved than the RNP1 (octapeptide) domains (Sutherland et al., 2005).  The N-
terminal and C-terminal portions of RBM5 produced in E.coli and HEK293 cells have 
been shown to preferentially bind poly (G) RNA homopolymer tracts in vitro (Drabkin et 
al., 1999; Edamatsu et al., 2000).  This is surprising since the C-terminal portion contains 
only the G-patch domain and a zinc finger domain but none of the RRM domains.  Along 
with two RRM domains RBM5 also contains two bipartite nuclear localization signals 
(NLS) and two types of zinc finger domains, C2H2 and RanBP2 type (C4).  RanBP2 
(Ran Binding Protein) zinc finger domains have been shown to bind RanGDP and 
exportin-1 proteins which regulate the nucleocytoplasmic transport within the cell (Singh 
et al., 1999).  Zinc finger of the C2H2 type mediating nucleic acid binding were first 
found in Xenopus oocytes transcription factor TFIIIA (Miller et al., 1985).  These 
domains are commonly found across the species in transcription factors such as EGR2 
and also Drosophila proteins Hunchback and Escargot to mention a few (Rosenfeld and 




In addition to the above mentioned domains there are also a number of low 
complexity regions within the RBM5 protein.  These regions are usually enriched in one 
or more amino acids.  The N-terminal region is rich in arginine residues and the C-
terminal contains the G-patch domain.  The G-patch domain is about 40 amino acids long 
with seven highly conserved glycine residues and is thought to aid in RNA binding 
(Aravind and Koonin, 1999).  OCRE (Octamer Repeat) domain consisting of imperfectly 
repeated octameric sequences forming a β-strand was recently described in RBM5 and 
VG5Q protein, an angiogenic factor implicated in a vascular disorder, the Klippel-
Trenaunay syndrome (Callebaut and Mornon, 2005).  Although, OCRE domains are 
common in a family of RNA binding motif proteins containing both RBM5 and RBM10, 
the function of this domain remains to be elucidated. 
 
 
RBM5 SPLICE VARIANTS 
 
Screening of multiple tissue northern blots have shown the presence of two 
RBM5 transcripts of 3.4 kb and 7.4 kb in length (Drabkin et al., 1999; Mourtada-
Maarabouni et al., 2002; this study).  The expression of RBM5 is highest in adult thymus, 
fetal kidney and is also expressed in various organs such as heart, brain, placenta and 
skeletal muscle (Drabkin et al., 1999; Lerman and Minna, 2000; Sutherland et al., 2000).  
Lerman and Minna have also reported presence of 1.5 kb and 2 kb RBM5 transcripts in 
some tissues, although these transcripts have not been detected either in this study or by 




et al. (2000 and 2005) by conducting RT-PCR with RBM5 specific primers (figure 13).  
The first splice variant RBM5+5+6 retains introns 5 and 6 and was discovered as a partial 
5' cDNA Clone 26 by Sutherland et al. (2000) and Clone 86 by Edamatsu et al. (2000).  
The full-length clone representing RBM5+5+6 has not yet been isolated.  Clone 26 codes 
for a 21 kDa protein when overexpressed in Jurkat cells or translated in vitro by rabbit 
reticulocyte lysate.  Depending on the molecular weight of the protein produced it seems 
that translation of the RBM5+5+6 mRNA terminates within intron 6 with the intron 5 
spliced out (Mourtada-Maarabouni et al., 2003).  The second splice variant RBM5+6 
retains intron 6 with the open reading frame also terminating within intron 6.  Although 
the predicted molecular weight of this splice variant is 17 kDa, this product has not been 
detected thus far.  The absence of any protein product corresponding to RBM5+5+6 and 
RBM5+6 transcripts may be attributed to nonsense-mediated decay (NMD) (Mourtada-
Maarabouni et al., 2003; Sutherland et al., 2005).  Both RBM5+5+6 and RBM5+6 splice 
variants appear to be represented by the 7.4 kb transcript on the northern analysis 
(Drabkin et al., 1999; Sutherland et al., 2000; this study).  The NMD hypothesis might be 
true since the amount of 7.4 kb transcript detected is always lower than the 3.4 kb 
transcript (this study). 
A third splice variant RBM5Δ6 without exon 6 overexpressed in three T-
leukaemic cell lines was cloned by Mourtada-Maarabouni et al. in 2003.  As seen from 
table 4 the RNP1 domain of RRM1 is coded for by exon 6.  RBM5Δ6 codes for a 17 kDa 
protein since deletion of exon 6 creates a frameshift mutation.  Lastly, a 326 bp Je2 
cDNA sequence antisense to intron 6 was isolated from bone marrow library.  




regulates 17 kDa protein probably coded by RBM5Δ6.  This finding cannot be explained 
by antisense effect of Je2 since neither full-length RBM5 not RBM5Δ6 contain intron 6 a 
region complimentary to Je2 (Sutherland et al., 2005). 
 
 














Figure 13:  Structure of RBM5 and its splice variants.  Full-length 3135 bp RBM5 (A) 
mRNA is made up of 25 exons coding for 815 amino acid protein with a molecular 
weight of 100-120 kDa.  The predicted stop codon within introns 6 and 5 (pink boxes) for 
RBM5+6 (B) and RBM+5+6 (C), respectively are shown as red boxes.  RBM5+6 and 
RBM+5+6 probably encode 7.4 kb transcript seen on northern blots.  A 326 bp antisense 
Je2 (green boxes) cDNA maps to a region within intron 6 of RBM5+6 and RBM+5+6 
splice variants.  Although, overexpression of Je2 protects cells from apoptosis the 
mechanism for this effect is not yet known.  The fourth splice variant RBM5Δ6 (D) 
encodes a 17 kDa protein since a frameshift mutation due to deletion of exon 6 leads to 
early termination of the transcript.  The exon and intron lengths are not drawn to scale.  







RBM5 - TUMOR SUPPRESSOR GENE AND APOPTOSIS REGULATOR 
 
RBM5 was first described as Gene 15 by Wei et al. (1996), as a potential tumor 
suppressor gene (TSG) since it was frequently deleted in various cancers and 100% 
deleted in non small cell lung carcinomas.  Scanlan et al. in 1999 using SEREX identified 
antibodies against Ren-9/RBM5 in patients suffering from renal cell carcinomas, thus 
identifying it as a potential tumor antigen.  The level of RBM5 was down-regulated in 
vestibular schwannomas and in rat cells transformed with a mutated constitutively active 
Ras (G12V) protein (Edamatsu et al., 2000; Welling et al., 2002).  However, the role of 
RBM5 as a TSG was disputed because of consistent expression and a lack of any 
sequence altering mutations within the RBM5 genomic region in several of the lung 
cancer cell lines studied (Lerman and Minna, 2000).  Also, RBM5 mRNA is up-regulated 
in many aggressive breast cancers expressing Her-2/neu oncogene (Oh et al., 1999).  
Some of the evidence summarized below however may suggest tumor suppressor activity 
of RBM5. 
Overexpression of full-length RBM5 in CEM-C7 T cells arrested the cell cycle in 
G1 phase and reduced the growth of MCF-7 RBM5-/- anchorage dependent and 
independent breast adenocarcinoma cells (Oh et al., 2002; Rintala-Maki et al., 2004b).  
Growth arrest was also observed in A9 mouse fibrosarcoma cells (anchorage 
independent) and A549 lung cancer cells (Oh et al., 2006).  Ectopic expression of RBM5 
along with subcutaneously injected A9 cells in nude mice resulted in tumor suppression 
(Oh et al., 2002).  Recent findings by Oh et al. (2006) and Mourtada-Maarabouni et al. 




arrest and apoptosis.  RBM5 sensitizes Jurkat T cells to apoptosis induced through Fas 
(CD95), TNF-α or TRAIL death receptor ligands (Rintala-Maki and Sutherland, 2004a).  
Downstream effects of RBM5 analyzed by microarray showed induction of Stat5b and 
BMP5 and down-regulation of Pim-1 (proto-oncogene), AIB1, BIRC3 (caspase 
antagonist) and CDK2 (Mourtada-Maarabouni et al., 2006).  Decreased levels of cyclin A 
and phosphorylated RB and increased expression of pro-apoptotic Bax protein were also 
observed in A549 lung cancer cells stably transfected with RBM5 (Oh et al., 2006).  
Together these results suggest that RBM5 may act as a tumor suppressor gene also 
regulating apoptosis. 
Given that full-length RBM5 is pro-apoptotic, splice variant RBM5Δ6 and 
antisense Je2 both act as anti-apoptotic.  Overexpression of antisense Je2 in CEM-C7 
cells rescues the cells from FasL, TNF-α and dexamethasone mediated apoptosis.  
Similar suppression of Fas mediated apoptosis by Je2 is also observed in Jurkat T cells 
(Mourtada-Maarabouni et al., 2002).  Cell proliferation and anti-apoptotic effects of 






RBM5/LUCA15 was first isolated in 1996 as a potential tumor suppressor gene 
frequently found deleted in the lung cancer hotspot 3p21.3.  Based on recent evidence it 




by apoptosis.  However, the exact pathway by which RBM5 and its splice variants can 
differentially mediate apoptosis is still unclear.  Up-regulation of RBM5 by Her-2/neu in 
breast cancer cells and as an immediate early gene by VEGF-A in endothelial cells seems 
anomalous with the current evidence and does not support the putative role of RBM5 as a 
TSG.  However, it should be noted that the putative VEGF-A induced immediate early 
gene set also contains negative regulators other than RBM5 such as DUSP1, ATF3 and 
EGR2 (Chapter 1, Part I). 
The following work in this dissertation is an attempt to understand and shed some 
light on RBM5.  Based on the domains present in RBM5 it can be hypothesized that 
RBM5 might be a nuclear protein and functions in RNA metabolism.  Chapter 2 in this 
section analyzes the localization of RBM5 in specific nuclear domains and also dissects 
the two bipartite NLS affecting its nuclear localization.  Moreover, the two bipartite NLS 
are differentially distributed in RBM5 and its splice variants.  Thus, determining the 
localization of RBM5 in specific nuclear domains might give a clue to the potential 
function of RBM5 and its splice variants.  Additionally, discerning the identity of the 
RNA species bound by RBM5 may abet in dissecting the mechanism by which it plays a 
seemingly common role in different scenarios of apoptosis, angiogenesis and tumor 
suppression.  Production of full-length RBM5 protein in vitro is a step closer towards the 
goal of identifying the family of RNA bound by RBM5 by conducting SNAAP analysis 
(Appendix A).  Finally, I have also attempted to analyze the signal transduction cascade 
emerging from VEGF-A leading to the induction of RBM5 by using inhibitors and 







SITE-DIRECTED MUTAGENESIS OF BIPARTITE NUCLEAR 





As discussed in chapter 1, RBM5 (RNA binding motif protein 5) a putative tumor 
suppressor gene and regulator of apoptosis is evolutionary conserved across a variety of 
organisms and taxa.  The RBM5 protein contains two RRM domains, two zinc finger 
motifs and two bipartite nuclear localization signals along with a G-patch domain.  The 
correct subcellular localization of a protein is essential to ensure its correct 
function/activity.  There are two bipartite nuclear localization signals (NLS) located near 
the N-terminal and C-terminals ends of RBM5 protein making it very likely that RBM5 is 
a nuclear protein. 
Ions and molecules smaller than 50-60 kDa can passively transit in and out of the 
double membrane bound nucleus gated by nuclear pore complexes (NPC).  However, 
larger molecules such as RNA and the 100-120 kDa RBM5 protein are actively 
transported through the NPC via a multi-step process by a superfamily of nuclear 
transport receptors known as importins or karyopherins.  Importin-α, containing an NLS-
binding site made of armadillo repeats, recognizes and binds to the cargo proteins to be 




Importin-β binds to this complex via the IBB (importin-β binding) domain on importin-α 
and docks it on the cytosolic face of NPC which then passes through to the nuclear side.  
In some cases importin-β can directly bind to the cargo protein, bypassing the adaptor 
protein importin-α (Pemberton and Paschal, 2005; Poon and Jans, 2005).  Binding of 
karyopherins to their cargo is mediated by small GTP binding proteins known as Ran 
(Ras-related nuclear protein).  Activity of Ran is in turn regulated by proteins controlling 
its GTPase activity (RanGEF and RanGAP) and its import back into the nucleus by NTF2 
(Moore, 1998; Pemberton and Paschal, 2005).  The entire process of nuclear import is 
thus dependent on the differential concentration of RanGTP in the nucleus as compared 
to that in the cytosol (figure 14).  In contrast to nuclear import, nuclear export depends on 
NES (nuclear export signal) and is mediated by exportins (CAS, Crm1).  No known NES 
domains have been predicted in RBM5 so far. 
A majority of the domains constituting the nuclear localization signals are made 
up of karyophilic clusters of the positively charged amino acid residues arginine and 
lysine (Boulikas, 1993).  Classical NLS are classified either as monopartite or bipartite.  
The first monopartite NLS (PKKKRKV) was discovered in SV40 large T antigen by 
Kalderon et al. in 1984.  Bipartite NLS with split clusters of karyophilic amino acids 
reconstituted by protein folding was first discovered in Xenopus nucleoplasmin protein 
by Robbins et al. in 1991.  The consensus for bipartite NLS is a cluster of positively 
charged amino acids (Arg/Lys) separated by 10-12 mutation tolerant spacer region 
followed by another cluster with at least three out of five amino acids being either 








Figure 14:  Key players of the nuclear import and export pathway.  Differential 
concentrations of small GTPase protein-Ran a key mediator of both the nuclear export 
and import pathway in nucleus and cytosol is regulated by NTF2, RanGAP and RanGEF 
(A).  Protein displaying NLS are transported inside the nucleus by forming a complex 
with importin-β alone or along with an adaptor protein importin-α (B).  Once the complex 
reaches the nucleus, RanGTP selectively binds to importin-β thereby, releasing the cargo.  
Importin-α is recycled back into the cytosol by exportin 2 or CAS (C).  The nuclear 
export also controlled by differential concentration of Ran operates in an opposite fashion 
as compared to nuclear import.  Nuclear export is dependent on NES domains and action 




Many nuclear proteins have atypical NLS instead of the classical monopartite or bipartite 
type.  The best known examples NLS domains deviating from the classical NLS are that 
found in c-Myc (PAAKRVKLD), KNS sequence of hnRNP K and the 38 amino acid M9 
signal of hnRNP A1 (Dang and Lee, 1988; Pollard et al, 1996; Michael et al., 1997). 
It is not uncommon to see nuclear proteins containing one or more functional 
NLS domains.  However, some cytosolic proteins also contain sequence motifs similar to 
bipartite NLS.  Thus, not all putative NLS are functional (Dingwall and Laskey, 1991; 
Zacksenhaus et al., 1993).  On the other hand, some cytosolic proteins such as hormone 
receptors (androgen receptor), transcription factors (p53, NFκB) or kinases (PKC, 
MAPK) when activated rapidly translocate to nucleus as a result of hidden or cryptic 
NLS exposed either by phosphorylation or dephosphorylation or dissociation of an 
inhibitory subunit (Shaulsky et al., 1990; Boulikas, 1993 and 1996; Kau and Silver, 2003; 
Pemberton and Paschal, 2005). 
Although nuclear localization of RBM5 was confirmed by Edamatsu et al. in 
2000 using RBM5 and c-myc epitope fusion construct, the subnuclear localization of 
RBM5 was not defined.  Using deletion mutagenesis on c-myc constructs they also 
suggested that the C-terminal NLS may be responsible for the nuclear localization of 
RBM5.  However, numerous studies have shown that the nucleus is organized in various 
subnuclear domains such as Cajal bodies, nucleoli, PML bodies, OPT domain nuclear 
speckles and paraspeckles (Spector, 2001).  Identifying the subnuclear localization of 
RBM5 may also help in predicting its probable function.  Therefore, I aimed to resolve 





Protein NLS Reference 
Monopartite NLS 
SV40 large T antigen 
PKKKRKV Kalderon et al., 1984 
v-Jun 
KSRKRKL Chida and Vogt, 1992 
Choline acetyltransferase 
ELPAPRRLRWK Gill et al., 2003 
Bipartite NLS 
Xenopus nucleoplasmin KRPAATKKAGQAKKKKLDK Robbins et al., 1991 
Human RB protein KRSAEGSNPPKPLKKLR Zacksenhaus et al., 1993 
S. cerevisiae SW15 KKYENVVIKRSPRKRGRPRK Moll et al., 1991 
Human IL 5 KKYIDGQKKKCGEERRRVNQ Jans et al., 1997 
Human p53 KRALPNNTSSSPQPKKKP Shaulsky et al., 1990 
Parafibromin (TSG) KRAADEVLAEAKKPR Hahn and Marsh, 2005 
Ste20-like protein kinase KKTSYLTELIDRYKRWK Lee et al., 2004 
Rbm5 NLS1 (putative) RRRDSDYKRSSDDRRGDRY 
Rbm5 NLS2 (putative) ERREKYGIPEPPEPKRKKQ 
Edamatsu et al., 2000 and this 
study 
Consensus K/R K/R-10-12 aa-K/R K/R K/R  
Atypical NLS 
RanBP3 PPVKRERTS Welch et al., 1999 
c-myc PAAKRVKLD Dang and Lee, 1988 
 
 
Table 5:  Examples of various types of nuclear localization signals (NLS) identified so 
far.  The consensus for monopartite NLS is a contiguous cluster of four to five 
karyophilic amino acids as compared to the bipartite NLS where the cluster is divided by 
a mutation resistant spacer region of 10-12 amino acids.  This table was partially adapted 





One of the major advantages of using EGFP to study localization is that recombinant 
fluorescent proteins can be discerned directly in live cells diminishing any fixation and 
staining artifacts introduced by processing cells for detection of epitope tags by indirect 
immunofluorescence.  Moreover, EGFP fusion constructs have been reliably used to 
discern the localization and dynamics of nuclear proteins in many studies (Phair and 
Misteli, 2000; Bubulya and Spector, 2004).  I further used this recombinant EGFPRBM5 
construct and engineered point mutations in individual RBM5 NLS to discern the 
functionality of the two bipartite NLS.  Dissecting the functional bipartite NLS of RBM5 
by site-directed mutagenesis instead of deletion mutants considerably improves the 
chances of conserving the protein confirmation of RBM5 thus, eliminating any false 
positive results obtained due to exposure of hidden NLS.  Results from this study indicate 
that RBM5 is localized in the nuclear speckles and its nuclear targeting is governed by 
only one bipartite NLS. 
 
 
MATERIALS AND METHODS 
 
Plasmid constructs 
Construction of pEGFPRBM5 - RBM5 coding sequence isolated from HUVEC 
cDNA by Dr. Brown in our lab was inserted into pEGFP-N2 vector MCS (Clontech) 
between the Sac I and EcoR I restriction sites.  The RBM5 open reading frame was 
extended into EGFP by changing the RBM5 stop codon (TGA) to glutamic acid (GAA) 




Construction of pEGFPRBM5NLS1M – The entire N-terminal bipartite NLS 
(NLS1) between Sac I and BsiHKA I (New England Biolabs) sites was mutated by PCR 
amplification in two overlapping pieces, NLS1MA and NLS1MB.  The two pieces were 
constructed using four oligonucleotides, with all the mutations engineered into two 
overlapping oligonucleotides spanning the first bipartite NLS.  The sequences (5'-3') of 
the four oligonucleotides depicting restriction sites (underlined), mutated nucleotides 
(bold) and overlapping section between the two oligonucleotides (italics) are as below:  
           Sac I 
1) NLS1.1 (GCGCGCGAGCTCATCGAAGGTCGCATGGGTTCAGAAAAA 
       CGAGTG) 
2) NLS1.2 (ATCATCACTAGAACTGTTGGAATCTGAGTCGCTCCCCTGCT) 
3) NLS1.3 (TCCAACAGTTCTAGTGATGATGGGAGCGGTGATAGTTATGAT) 
       EcoR I    BsiHKA I 
4) NLS1.4 (GCGCGCGAATTCGTGCTCACCATAGTCACCATCTGAATG) 
RBM5 coding sequence spliced out from pEGFPRBM5 (Sac I-EcoR I) and gel purified 
using DEAE membrane (see Chapter 2, Part 1) was used as a template in a 50 µl PCR 
reaction to make two pieces (A and B) of NLS1M as follows: 
10X Advantage 2 PCR buffer (Clontech)   5 µl 
50X dNTP        1 µl 
10 µM NLS1.1 (A)/NLS1.3 (B)    2 µl 
10 µM NLS1.2 (A)/NLS1.4 (B)    2 µl 
Sac I - EcoR I (pEGFP)RBM5    1 µl (25 ng) 
50X polymerase      1 µl 
The PCR cycle parameters used were: 1X 95ºC/1 minute; 9X 95ºC/30 seconds, 60ºC/30 




made by PCR were gel purified using DEAE membrane, redissolved in 25 µl of dH20 and 
used to reconstruct the entire NLS1M by PCR as follows: 
NLS1MA       1 µl 
NLS1MB       1 µl 
10 µM NLS1.1      2 µl 
10 µM NLS1.4      2 µl 
10X Advantage 2 PCR buffer (Clontech)   5 µl 
50X dNTP        1 µl 
50X polymerase      1 µl 
The PCR cycle parameters used were: 1X 95ºC/1 minute; 9X 95ºC/30 seconds, 37ºC/30 
seconds, 68ºC/1 minute and 14X 95ºC/30 seconds, 68ºC/1 minute.  The amplified 
NLS1M was gel purified and digested with Sac I and EcoR I (Promega) enzymes and 
ligated into CIP dephosphorylated pGEM®3Z(f+) vector digested with the same enzymes.  
Competent JM109 cells (Promega) were transformed with this ligation mixture and 
plated on LB agar plates containing 100 µg/ml ampicillin.  After overnight incubation at 
37°C the recombinant colonies were picked up and processed further for plasmid 
isolation as described before in Chapter 2, Part 1.  Presence of NLS1M insert was 
confirmed by dye terminator sequencing method at our campus facility.  The NLS1M 
insert was spliced out from pGEM®3Z(f+)NLS1M using Sac I and BsiHKA I, gel 
purified and used to construct pEGFPRBM5NLS1M by performing a three fragment 
ligation as follows: 
(Sac I - EcoR I) CIP dephosphorylated pEGFP-N2 vector 1µl (100 ng) 




(BsiHKA I - EcoR I) RBM5     1 µl (50 ng) 
10X T4 DNA ligase buffer (Promega)   1 µl 
T4 DNA ligase      1 µl 
dH2O        5 µl 
Ligation reaction was incubated overnight at 16ºC.  Competent JM109 cells were 
transformed with the above ligation reaction and plated on LB agar plates containing 30 
µg/ml of kanamycin.  After, overnight incubation recombinant colonies were processed 
for plasmid isolation and sequenced to confirm the orientation of ligations as described 
before. 
Construction of pEGFPRBM5NLS2M – The second bipartite NLS flanked by the 
Nhe I and EcoR I sites was mutated by assembling two pieces NLS2MA and NLS2MB 
using the same PCR amplification strategy used to construct NLS1M.  The sequences (5'-
3') of the four oligonucleotides depicting restriction sites (underlined), mutated 
nucleotides (bold) and overlapping section between the two oligonucleotides (italics) are 
as below: 
   BamH I    Nhe I 
1) NLS2.1 (GCGCGCGGATCCGCTAGCTGACTGGAAGAAGATG) 
2) NLS2.2 (TGGAGGTTCTGGAATGCCGGAGTTCTCCCCACTTTCTGC) 
3) NLS2.3 (GAGAACTCCGGCATTCCAGAACCTCCAGAGCCCAACGGCAACAA 
       CCAGTTT) 
   EcoR I 
4) NLS2.4 (GCGCGCGAATTCCTCCATCTCAGTGAACCGGGCAAAC) 
The pEGFPNLS2M construct was assembled by performing three fragment ligation of 
Sac I - EcoR I (CIP) pEGFP-N2 vector, Sac I - Nhe I RBM5 and Nhe I - EcoR I digested 




Recombinant clones obtained by subsequent transformation of competent JM109 were 
scaled up and sequenced to confirm the site-directed mutagenesis of NLS2M. 
Construction of pEGFPRBM5NLS1MNLS2M – Constructs with both the bipartite 
NLS mutated were constructed in parallel to pEGFPRBM5NLS2M by substituting Sac I-
Nhe I RBM5NLS1M instead of Sac I-Nhe I RBM5 in the above three fragment ligation 
reaction.  All procedures subsequent to ligation were carried out similar to that for 
construction of pEGFPRBM5NLS2M.  Mutations were confirmed by sequencing. 
 
Cell culture 
HT-6 cells (SV40 large T-antigen transformed immortalized HUVEC cells) 
produced in our lab by Dr. Brown and pooled HUVEC cells were grown in EGM 
medium supplemented with 1 ng/ml of bFGF as mentioned in Chapter 2 (Part I).  
NIH3T3 cells and HepG2 cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal calf serum, 50 units/ml penicillin, 50 μg/ml streptomycin 
(Invitrogen) and 200 ng/ml amphotericin B (Sigma Aldrich) at 37ºC in a 5% CO2 
humidified incubator.  Before transfection cells were harvested using ice cold 1 mM 
EDTA in PBS and grown on 22 X 22 mm Corning® number 1½ cover glasses or in Lab-
Tek™ four well chambered cover glasses (Nalge Nunc International). 
 
Transient transfections 
Each plasmid construct (1-3 μg per cover glass of cells) was diluted in 99 μl of 
Opti-MEM I reduced serum medium (Invitrogen).  Simultaneously, 6 μl of Lipofectin® 




30 minutes.  The plasmid and the Lipofectin® dilutions were then combined and further 
incubated for 15 more minutes, following which 0.8 ml of Opti-MEM I was added.  This 
mixture was used to transiently transfect cells pre-washed with 2 ml of Opti-MEM I.  
After 3 hours of incubation at 37°C/5% CO2 the cells were allowed to recover in 
respective cell culture media for 18-20 hours.  For transcription inhibition studies cells 




Organelle staining - Cellular organelles were stained with either 500 nM 
MitoTracker Red CMXRos (mitochondria/45 minutes) or 75 nM LysoTracker Red DND-
99 (lysosomes/1 hour).  Cells on each cover glass were fixed with 3.7% formaldehyde in 
cell culture medium for 15 minutes at room temperature and subsequently washed five 
times in 1 ml of PBS each.  Cells were then permeabilized using 1 ml of 0.2% Triton X-
100 in PBS for 5 minutes at room temperature and then washed twice in PBS.  
Alternatively, cells were fixed and permeabilized in 100% acetone at -20ºC for 1 minute 
and then rinsed several times in PBS to remove any traces of acetone.  Subsequently, 
cells were either stained for five minutes with 300 nM DAPI (nuclear DNA) or further 
processed for indirect immunofluorescence as given below.  Live cells were stained as 
above and visualized in respective cell culture media after extensive washings to remove 
unincorporated dyes.  Excitation and emission spectra of all the fluorescent dyes used in 




Indirect immunofluorescence – Non-snRNP splicing factor SC35 was detected by 
incubating fixed and permeabilized cells in 1 ml of 1:1,000 diluted anti SC35 monoclonal 
IgG1 antibody (Sigma Aldrich, USA) per cover glass for 1 hour at 4ºC.  Unbound 
primary antibody was washed off by rinsing the cells in PBS for 5 minutes each.  Bound 
primary antibody was detected by using 10 µg/ml Alexa Fluor® 633 (figure 15) goat 
anti-mouse IgG (H+L) (Invitrogen) per cover glass for 1 hour at 4ºC.  For microscopy, 
cover glasses were washed four times in PBS and mounted on slides in a drop of 









4', 6-diamidino-2-phenylindole, dihydrochloride (DAPI) 
Enhanced green fluorescent protein (EGFP) 
LysoTracker Red DND-99 
MitoTracker Red CMXRos 
Alexa Fluor®633 goat anti-mouse antibody  
 
 
Figure 15:  Excitation (dotted lines) and emission (bold lines) spectra of various 
fluorescent molecules used in this study are illustrated.  Wavelength of the light in 
nanometers is displayed on X-axis and the percent fluorescence is displayed on the Y-
axis.  This figure was configured and adapted from the Fluorescence Spectraviewer 





Microscopy - Live and fixed cells were observed using 63X water and 100X oil 
immersion lenses, respectively on either Zeiss LSM 510 confocal or Deltavision 
deconvolution microscopes at our campus facility.  Channel colors green (EGFP), pink 
(Alexa Fluor® 633) and red (MitoTracker Red CMXRos or LysoTracker Red DND-99) 
are digitally assigned after scanning the sample. 
Colocalization parameters – The following quantitative parameters available in 
the Zeiss colocalization software were used for determining the colocalization between 
two colored pixels, green (Ch1) and red/pink (Ch2). 
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Values of the first three quantitative colocalization parameters range between 0 (no 
colocalization) and 1 (all pixels colocalize).  Pearson’s correlation coefficient values lie 





Colocalization of RBM5 in nuclear speckles 
Based on the fact that RBM5 has two bipartite NLS, it is reasonable to suspect 
that RBM5 may localize to nucleus.  Transient transfection of HUVEC cells with 
pEGFPRBM5 indeed shows a diffuse nuclear localization pattern with majority of the 
fluorescence concentrated in 25-50 distinct speckles, with no fluorescence detected in 
nucleoli or cytosol.  This pattern of localization is similar to that of IGCs (interchromatin 
granule clusters) or nuclear speckles which are enriched in pre-mRNA splicing factors.  
Localization of RBM5 in nuclear speckles was replicated for both live and fixed cells in 
various cell lines (HUVEC, HT-6, NIH3T3 and HepG2) ruling out any discrepancy 
caused due to fixation artifacts (figure 16A). 
Previous studies have demonstrated that nuclear speckles contain little or no 
chromatin.  Most of the speckles are observed at the periphery of the active transcription 
sites (Misteli, 2000; Lamond and Spector, 2003).  Predictably, staining for nuclear DNA 
with DAPI shows no discernable presence of chromatin within the RBM5 nuclear 
speckles (figure 16B).  Despite the fact that nuclear speckles contain many pre-mRNA 




but, are rather thought to be storehouses from which these factors are recruited to sites of 
transcription.  This dynamic of nature of nuclear speckles can be disrupted by inhibiting 
transcription using heat shock (45ºC/15 minutes) or transcriptional inhibitors such as 
actinomycin D (10 µg/ml/3 hours) or α-amanitin (50 µg/ml/5 hours) (Carmo-Fonseca et 
al., 1992; Lamond and Spector, 2003; Shav-Tal et al., 2005).  Protocols for disruption of 
transcription in cell culture are well established in the literature.  It should be noted that, 
the time and concentrations of transcriptional inhibitors (actinomycin D and α-amanitin) 
used throughout this study potently inhibit RNA polymerase II.  As expected, inhibition 
of transcription by actinomycin D or α-amanitin dramatically changed the nuclear speckle 
organization of RBM5 with all the fluorescence concentrated in 3-4 rounded clusters 
measuring 2-3 µm across (figure 16C and 16D).  Thus, the absence of DNA and 
clustering in presence of transcriptional inhibitors are key characteristics displayed by 
nuclear speckle proteins.  Although RBM5 demonstrated both of these distinguishing 
characteristics, the presence of RBM5 in nuclear speckles was further confirmed by 
colocalization with another well characterized nuclear speckle protein SC35. 
Colocalization of transiently transfected pEGFPRBM5 (green) with SC35 (pink) 
labeled with indirect immunofluorescence was quantified for various colocalization 
parameters using LSM510 Image Examiner software available from Zeiss.  As seen from 
figure 17A RBM5 (green) shows a great degree of colocalization with SC35 (pink).  
Colocalization and weighted colocalization coefficients are the most commonly used 
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Figure 16:  Localization of EGFPRBM5 in nuclear speckles.  Localization of RBM5 as 
determined by expression of pEGFPRBM5 transiently transfected in HUVEC cells by 
Lipofectin.  RBM5 shows a characteristic nuclear speckle localization in both live (A) 
and fixed cells (B).  For live cell microscopy, cells grown and transiently transfected on 
chambered cover glasses were processed further for fluorescence microscopy using 63X 
water immersion lens and Zeiss LSM 510 confocal microscope.  Nuclear boundary was 
determined by Nomarski (DIC) image shown here as an overlay of two images.  RBM5 
associated fluorescence (green) is excluded from chromatin stained blue with DAPI (B).  
Treatment of cells with transcriptional inhibitors actinomycin D (10 µg/ml/3 hrs) (C) and 
α-amanitin (50 µg/ml/5 hrs) (D) results in clustering of EGFPRBM5, a feature shared by 
proteins localized in nuclear speckles.  Overall cellular architecture is highlighted by 
staining the cells with MitoTracker Red CMXRos (B, C and D).  Staining and fixation 
techniques are as detailed in Materials and Methods.  Images in part B were taken using a 
100X oil immersion lens and Deltavision deconvolution microscope and is a 
representative of image stacks obtained after running deconvolution algorithms.  Images 




Colocalization coefficients measure the relative number of colocalizing pixels in two 
channels green (EGFPRBM5) and pink (SC35).  The values indicate that 97% of pink 
pixels colocalize with 95% green pixels (figure 17C).  Weighted colocalization 
coefficients show a higher degree (100%) of colocalization since more weight is given to 
brighter pixels in both the channels.  Overlap coefficient (Manders coefficient) is a 
convenient but relatively insensitive parameter to compare the degree of overlap between 
the two channels, which in this case is 0.9 or 90% overlap (Manders et al., 1993).  A 
much more sensitive parameter to measure colocalization is the Pearson’s correlation 
coefficient (R) which in this case shows a lower value of 0.83 or 83% colocalization.  
This lower value can be partly explained by the fact that there are many more green 
pixels due to overexpression of RBM5 as compared to pink pixels attributed to native 
SC35.  All computations were performed by taking into account the background pixels 
which are defined by randomly assigning an ROI (region of interest) removed from the 
area marked for determination of colocalization.  Similar calculations were repeated for 
at least 15 different nuclei from various cell lines in more than three independent 
experiments.  Pearson’s correlation coefficient values ranging from 0.6-0.8 were 
routinely obtained.  All images were obtained by scanning the cells sequentially with 
each laser (488 nm and 633 nm) to avoid any observed colocalization due to bleed 
through between the two channels.  Absence of any channel crosstalk was also confirmed 



















































































































































































































































































































































Figure 17:  Colocalization of EGFPRBM5 with SC35.  Colocalization of RBM5 (green) 
with SC35 (pink) in HUVEC cells (A) was calculated using the Zeiss colocalization 
software.  Background fluorescence was adjusted by randomly defining an area (region 
1) outside the cellular boundaries.  For estimating colocalization, nuclear area including 
SC35 and RBM5 fluorescence was defined by region 2 also represented as a scattergram 
on the left side (B).  The third quadrant of scattergram represents colocalizing pixels from 
green and pink channels.  Various parameters for EGFPRBM5 (Ch3-T2) and SC35 (Ch1-
T1) fluorescence are highlighted under green and pink channels respectively (C).  As 
seen from the colocalization coefficient, 97% of the pink (SC35) pixels colocalize with 
95% of the green (EGFPRBM5) pixels.  Weighted colocalization coefficient calculates a 
100% colocalization since more weight is given to brighter pixels than duller ones.  This 
high degree of overlap between the SC35 and EGFPRBM5 is also reflected by overlap 
coefficient value of 0.9.  A much more sensitive parameter, Pearson’s correlation 
coefficient (R) is slightly lower with a value of 0.83.  This colocalization is representative 
of similar estimations done for at least 15 different cells from more than three 



















Colocalization of RBM5 and SC35 in transcriptionally inhibited cells 
As mentioned before, transcriptional inhibition results in nuclear speckle proteins 
including RBM5 to concentrate in 3-4 clusters.  Colocalization for RBM5 and SC35 in 
presence of actinomycin D and α-amanitin was determined based on the hypothesis that if 
indeed both the proteins are localized in the nuclear speckles then they must be equally 
affected by transcriptional inhibitors.  The redistribution of a non-snRNP spliceosome 
component and nuclear speckle protein, SC35 due to transcription inhibition is well 
documented and was first demonstrated by Spector et al. in 1991.  Indeed both RBM5 
and SC35 display the same loss of speckled localization and share a common pattern of 
clustering when treated with either actinomycin D or α-amanitin, transcriptional 
inhibitors with different modes of action (figure 18A and 19A).  Although, the pattern of 
localization for both the proteins is similar, there is very little colocalization as 
determined from low Pearson’s correlation coefficient of 0.43 and 0.3 for α-amanitin and 
actinomycin D, respectively (figure 18C and 19C).  Clusters of both RBM5 and SC35 
appear to lie adjacent to each other with a small band of colocalization between them.  
This pattern of localization for RBM5 and SC35 in transcriptionally inhibited cells was 























































































































































































































































































































































Figure 18:  Colocalization of EGFPRBM5 with SC35 in presence of α-amanitin.  Cells 
transiently transfected with pEGFPRBM5 (green) were pretreated with 50 µg/ml (5 
hours) α-amanitin for transcriptional inhibition before fixing and staining for non snRNP 
protein SC35 (pink).  Both RBM5 and nuclear speckle protein SC35 behave in a similar 
fashion and form rounded clusters when transcription is shut down (A).  However, both 
RBM5 and SC35 proteins do not colocalize as seen before in absence of any 
transcriptional inhibitors but, are instead side by side with a small band between them 
displaying colocalization.  The Pearson’s correlation coefficient is correspondingly lower 
at 0.43 (region 2) (B and C).  This experiment is representative of more than three 
independent experiments and more than 12 different nuclei.  Pearson’s correlation 
coefficient value between 0.3-0.4 was routinely obtained.  Background fluorescence was 





































































































































































































































































































































































Figure 19:  Colocalization of EGFPRBM5 with SC35 in presence of actinomycin D.  
Cells transiently transfected with pEGFPRBM5 construct were transcriptionally inhibited 
by treating with 10 µg/ml actinomycin D for 3 hours.  Both RBM5 and SC35 round up 
when treated with actinomycin D, in a similar pattern also observed above in cells treated 
with α-amanitin.  RBM5 (green) and SC35 (red) clusters are localized adjacently with 
only a small band showing colocalization between the two proteins, reflected by a 
correspondingly lower Pearson’s correlation value of 0.3.  Series of similar estimations 
for more than ten different nuclei from more than three independent experiments 
consistently gave an overlap coefficient of 0.8 and a Pearson’s correlation coefficient 






















Accuracy of colocalization measurements 
Having determined the colocalization of RBM5 with SC35 in nuclear speckles, 
question remained if the values calculated were indeed accurate and sensitive enough to 
predict colocalization between two channels.  To test this, experiments analogous to those 
for determining the RBM5 and SC35 colocalization were set up.  An empty pEGFP-N2 
vector instead of EGFPRBM5 was used to transfect the cells transiently and determine 
the colocalization with SC35 (figure 20A).  The 27 kDa native EGFP can passively 
diffuse inside the nuclei and does not need any nuclear localization signals.  As seen from 
figure 20A an excess of EGFP completely overlaps the SC35 present in the nucleus.  All 
colocalization estimations were done after eliminating any fluorescence contributed by 
background pixels.  Colocalization and weighted colocalization coefficient values 
indicate that SC35 (pink) completely colocalizes with most of the EGFP (green) with an 
80% overlap between the two channels (figure 20C).  However, the Pearson’s correlation 
value of zero indicates that there is no correlation between two channels.  Similar low 
Pearson’s correlation coefficients were obtained in three repetitions.  Thus, the degree of 
colocalization between two proteins is best determined by taking into account all the 












































































































































































































































































































































Figure 20:  Colocalization of EGFP (control) with SC35.  The software efficacy in 
determining the colocalization was tested by transfecting the cells with pEGFP-N2 vector 
alone and subsequently localizing SC35 (Alexa Fluor® 633) by indirect 
immunofluorescence as done for experiments with pEGFPRBM5.  As expected, the 27 
kDa EGFP protein shows a diffuse cytosolic and nuclear distribution (A).  After adjusting 
the background fluorescence highlighted as region 1, nuclear colocalization was 
determined for region 2 containing EGFP and SC35 (B).  Although, the overlap 
coefficient is 0.8 and colocalization coefficient for pink pixels is the highest (1.0), there is 
no colocalization of EGFP and SC35 as determined by the zero value of Pearson’s 
correlation coefficient (C).  Channels for EGFP and SC35 are highlighted by their 
respective colors green and pink.  This experiment is representative of three separate 
colocalization determinations done in a similar way.  Pearson’s correlation coefficient 





















Site-directed mutagenesis of N-terminal bipartite NLS (NLS1) 
As detailed in the Materials and Methods section, the strategy of introducing point 
mutations instead of deletion mutagenesis was used to change the overall structure of the 
bipartite NLS (figure 21A and 21B).  As compared to deletion mutagenesis, this 
technique conserves the overall structure of the protein to a large extent thereby 
increasing the chances of mimicking the true protein architecture in vivo and also 
considerably reducing the chances of false positive results due to exposure of cryptic 
NLS.  The N-terminal NLS is well conserved among the RBM5 proteins across species 
(figure 21C).  All the karyophilic amino acids making up the bipartite NLS were replaced 
by uncharged amino acids glycine or serine by changing a single base in each codon 
representing the same.  Transient transfection of pEGFPRBM5NLS1M and subsequent 
colocalization studies with SC35 demonstrate that the mutant NLS1M not only retains 
nuclear targeting and but is also localized in speckles, similar to the non-mutated form of 
RBM5 (figure 22 and 23A).  These results were consistently observed in both live and 
fixed cells from different human and mouse cell lines.  A representative example of 
colocalization calculations for RBM5NLS1M and SC35 shows a similar range of values 
for quantitative parameters as demonstrated for the parent molecule - RBM5 (figure 
23C).  Colocalization and weighted colocalization coefficients both reveal complete 
(100%) colocalization of SC35 (pink) with RBM5NLS1M.  This result is confirmed by a 
high overlap coefficient value of 0.9 or 90%.  As seen before for RBM5 there are more 
green pixels (RBM5NLS1M) than for native SC35 which might be responsible for 90% 
overlap coefficient and a slightly lower Pearson’s correlation coefficient value of 0.61. 





easily affected if one protein is overexpressed, even a lower value is statistically 
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  R  R  R  D  S  D  Y  K  R  S  S  D  D  R  R  G  D  R  Y  
 AGGCGGAGGGACTCAGATTACAAAAGATCTAGTGATGATCGGAGGGGTGATAGATAT 
 ||| |||| |||||||||| ||| || |||||||||||| |||| |||||||| ||| 
 AGGGGGAGCGACTCAGATTCCAACAGTTCTAGTGATGATGGGAGCGGTGATAGTTAT 




NP_005769.1:    Homo sapiens (RBM5)  34  RRDSDYKRSSDDRRGDR  50 
XP_517024.1:    Pan troglodytes (RBM5) 34  .................  50 
AAH31899.1:     Mus musculus (RBM5)  34  .................  50 
XP_885474.1:    Bos Taurus (RBM5)  34  .................  50 
XP_861224.1:    Canis familiaris (RBM5) 34  .................  50 
XP_217263.3:    Rattus norvegicus (RBM5) 34  .................  50 
NP_001012798.1: Gallus gallus (RBM5)  33  ..RD......EE.....  49 




Figure 21:  Strategy for site-directed mutagenesis of RBM5NLS1M.  The first bipartite 
NLS (pink box) of RBM5 (blue box) was mutated by constructing two pairs of 
oligonucleotides amplifying overlapping regions of NLS1 as shown in part A and 
detailed in Materials and Methods.  All the point mutations for site-directed mutagenesis 
of NLS1 (B) were engineered in the two overlapping oligonucleotides NLS1.2 and 
NLS1.3.  The first bipartite NLS is well conserved across the species except in chickens 
where there is a discrepancy in four amino acid residues outside the bipartite NLS shaded 
in green.  Homology search was done by running the BLASP algorithm available through 
NCBI.  Figures are not drawn to scale. 

































      B
) 




Figure 22:  Localization of EGFPRBM5NLS1M in nuclear speckles as seen in live 
HUVEC cells (A) and in HT-6 cells (B).  SC35 in HT-6 cells was visualized by indirect 
immunofluorescence using monoclonal anti-SC35 and goat anti-mouse Alexa Fluor 633 
as detailed in Material and Methods.  Images were captured using 63X water immersion 
lens (A) and 100X oil immersion lens on Zeiss LSM 510 confocal microscope.  Image B 















































































































































































































































































































































































Figure 23:  Colocalization of RBM5NLS1M with SC35.  Transient transfection and 
colocalization studies of pEGFPRBM5NLS1M (green) with SC35 (pink) reveal the same 
results as those obtained for pEGFPRBM5.  Resident of nuclear speckles, SC35 is 
completely colocalized with an excess of RBM5NLS1M as seen from the colocalization 
coefficient and overlap coefficient values.  A slightly lower Pearson’s correlation value 
of 0.61 also reflects the excess of green pixels as compared to the pink pixels.  These set 
of calculation represent similar experiment done in various human and mouse cell lines 























Site-directed mutagenesis of C-terminal bipartite NLS (NLS2M) 
An approach similar to mutation of N-terminal bipartite NLS (NLS1) was used to 
mutate the second bipartite NLS (NLS2) located at the C-terminal end of the RBM5 
protein, preceding the EGFP coding sequence in the fusion construct (figure 24A).  An 
overview of the mutations introduced to completely change characteristic arrangement of 
charged residues in the bipartite NLS is outlined in figure 24B.  Protein BLAST 
(BLASTP) analysis reveals that NLS2 is not only conserved in RBM5 proteins across 
species but is also remarkably well conserved in RBM10 with minor replacements of one 
karyophilic amino acid with another (figure 24C).  Transient transfection studies reveal 
that unlike NLS1M, NLS2M completely disrupts the nuclear translocation of the mutated 
RBM5 protein.  The observed EGFPRBM5NLS2M fluorescence was in many cases faint 
and indistinguishable from the background due to a decreased signal to noise ratio.  Since 
it was difficult to locate many transfected cells after the normal fixation and SC35 
staining techniques, I decided to observe live transfected cells and switch to new, quicker 
acetone fixation techniques as detailed in Material and Methods.  Adoption of these new 
techniques not only dramatically changed the results obtained for EGFPRBM5NLS2M, 
but also increased the number of transfected cells visualized.  This acetone fixation 
however did not alter the localization of either EGFPRBM5 or EGFPRBM5NLS1M in 
nuclear speckles as validated by additional SC35 colocalization studies done as before.  
Instead of diffuse cytosolic staining obtained by traditional formaldehyde/Triton X-100 
fixation and permeabilization techniques (figure 25A), EGFPRBM5NLS2M fluorescence 
was observed as discrete spots outside the nucleus reminiscent of lysosomal localization 




dye which specifically stains acidic organelles shows complete colocalization with 
pEGFPRBM5NLS2M (figure 25D).  Absence of autofluorescence and channel crosstalk 
was ascertained by detecting EGFP or LysoTracker Red alone in both the channels 
scanned by single track scans and also by switching the order of channels scanned in cells 
dually labeled. 
Thus, it is clear that the C-terminal bipartite NLS (NLS2M) is the functional NLS 
responsible for targeting full-length RBM5 protein into the nucleus and its subsequent 
localization in splicing factor enriched nuclear speckles.  Disruption of both the N- and 
C-terminal bipartite NLS (pEGFPRBMNLS1MNLS2M) also gave identical results of 
disrupted nuclear targeting and colocalization with lysosomes as obtained for the mutated 
NLS2M.  This again confirms that the C-terminal NLS (NLS2) mediates nuclear 
targeting of RBM5 either because it is exposed or is the only functional NLS present.  In 
retrospect, the difficulty in observing the mislocalized proteins by EGFP fluorescence can 
be explained by the fact that the EGFP is quenched by almost 50% at acidic pH – a 
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 E  R  R  E  K  Y  G  I  P  E  P  P  E  P  K  R  K  K  Q  
GAAAGACGGGAGAAGTACGGCATTCCAGAACCTCCAGAGCCCAAGCGCAAGAAGCAG 
|||||  ||||||| | |||||||||||||||||||||||||||  |||| || ||| 
GAAAGTGGGGAGAACTCCGGCATTCCAGAACCTCCAGAGCCCAACGGCAACAACCAG  





NP_005769.1:    Homo sapiens (RBM5)  708  RREKYGIPEPPEPKRKK  724 
AAH31899.1:     Mus musculus (RBM5)  708  .................  724 
XP_885474.1:    Bos taurus (RBM5)   649  .................  665 
XP_861224.1:    Canis familiaris (RBM5)  634  .................  650 
CAJ81574.1:     Xenopus tropicalis (RBM5)  725  ................R  741 
AAH77408.1:     Xenopus laevis (RBM5)  643  ................R  659 
XP_694937.1:    Danio rerio (RBM5-prov)  605  ...........V..KR.  621 
NP_005667.2:    Homo sapiens (RBM10)  821  ...............R.  837 
XP_521033.1:    Pan troglodytes (RBM10)  111  ...............R.  127 
XP_582084.2:    Bos taurus (RBM10)  658  ...............R.  674 
XP_538013.2:    Canis familiaris (RBM10)  895  ...............R.  911 
XP_913742.1:    Mus musculus (RBM10)  743  ...............R.  759 
NP_690600.1:    Rattus norvegicus (RBM10)  743  ...............R.  759 




Figure 24:  Strategy for site-directed mutagenesis of RBM5NLS2M.  The second 
bipartite NLS (pink box) located near the C-terminal end of RBM5 (blue box) was 
mutated by constructing four oligonucleotides (A) containing the point mutations as done 
for constructing NLS1M.  Part B shows all the point mutations engineered for site-
directed mutagenesis of NLS2M.  BLASTP analysis reveals that the second bipartite 
NLS is conserved across the species not only in RBM5 but also in RBM10 which is 
present on chromosome Xp11.3-11.23 in humans and also shares a 51% homology to 
RBM5.  Figures are not drawn to scale.  BLASTP search algorithm is available online 
from NCBI (www.ncbi.nlm.nih.gov). 
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Figure 25:  Localization of EGFPRBM5NLS2M.  Site-directed mutagenesis of the C-
terminal bipartite NLS (NLS2) in full-length RBM5 tagged with EGFP disrupts its 
nuclear localization.  Cells processed for SC35 labeling by formaldehyde fixation and 
Triton X-100 permeabilization (A) demonstrate an appreciably different localization 
pattern of RBM5NLS2M as compared to live cells (B).  Cell fixation with -20ºC 
acetone for one minute replicates the data obtained in live cells (C).  Live HUVEC 
cells dually stained with LysoTracker Red DND-99 reveals that 
pEGFPRBM5NLS2M is targeted to acidic organelles or lysosomes (D).  Green 
fluorescence (EGFP) completely colocalizes with a fraction of the red fluorescence 
contributed by LysoTracker Red DND-99.  Although, all the above images represent 
HUVEC cells, similar experiments repeated in NIH3T3 and HT-6 cells with either 
pEGFPRBM5NLS2M or pEGFPNLS1MNLS2M lead to same results.  There was no 























Localization of 815 amino acid full-length RBM5 in nuclear speckles or 
interchromatin granule clusters (IGCs) was confirmed in this study by creating fusion 
constructs with enhanced green fluorescent protein.  Although a previous study by 
Edamatsu et al. (2000) confirmed the nuclear targeting of RBM5 by c-myc fusion 
constructs and indirect immunofluorescence, its subnuclear localization was not clear.  
Previous studies have demonstrated that the cell nuclei are organized in many specific 
domains apart from the most clearly visualized cell nucleoli involved in synthesis and 
processing of ribosomal RNA and assembly of ribosomal subunits (Spector 2001).  
Correct compartmentalization of any protein is not only essential for its individual 
activity but can also provide essential clues about the structure and functional 
relationship of an unknown protein.  Some of the nuclear domains discovered so far 
are Cajal/Coiled bodies (snRNP biogenesis, snRNP and snoRNP trafficking), Gems 
(snRNP assembly), cleavage bodies (cleavage and polyadenylation steps of pre-
mRNA processing), PML bodies (transcriptional regulation), nuclear speckles (pre-
mRNA splicing factors) and paraspeckles (Spector, 2001, 2003). 
Colocalization studies of EGFP tagged RBM5 with another frequently used 
non-snRNP nuclear speckle protein SC35 demonstrated that RBM5 localizes to 
nuclear speckles.  This hypothesis was further confirmed by the fact that there is a 
drastic change in the unique nuclear speckle compartmentalization of RBM5 in the 
presence of transcriptional inhibitors, mimicking a characteristic displayed by 




another key feature attributed to nuclear speckle proteins was also confirmed in this 
study.  A high overlap coefficient value ranging from 80% to 90% combined with a 
Pearson’s correlation coefficient value ranging from 0.6-0.8 indicates that the two 
proteins are not perfectly colocalized.  Although, it must be noted that for 
colocalization computations done in this study, EGFPRBM5 was relatively 
overexpressed as compared to the native SC35 protein stained by indirect 
immunofluorescence.  Thus, a variation in the observed Pearson’s correlation values 
can be attributed to experimental variation in SC35 staining technique, un-localized 
excess EGFPRBM5 or indeed that the two proteins do not colocalize completely.  
Colocaliztion studies of RBM5 and SC35 in the presence of transcription inhibitors 
although displays a same rearrangement pattern, the degree of overlap is less than that 
seen in untreated cells.  This difference suggests that either overexpressed RBM5 
causes SC35 displacement or else the two proteins are not perfectly colocalized and 
this result may have been amplified in the presence of transcription inhibitors which 
cause clustering of proteins in fewer speckles.  However, it is now a well known fact 
that various subdomains known as subspeckles exist within the nuclear speckle 
domains.  This subspeckle architecture was demonstrated by staining various RNA 
processing factors using high antibody titers (Mintz and Spector, 2000).  It is possible 
that both RBM5 and SC35 are present in nuclear speckles but in separate subspeckles.  
However, these questions can only be effectively addressed if the relative expression 
of the two proteins is comparable and the same techniques are used to identify both 




antibody capable of labeling nuclear speckles.  In the future FRET analysis could be 
used to assess interactions between RBM5 and other nuclear speckle proteins. 
Based on the localization of RBM5 in nuclear speckles and the presence of 
RNA binding motifs, it is possible that full-length RBM5 is involved in pre-mRNA 
processing.  Biochemical isolation of nuclear speckles coupled with proteomic 
analyses by Saitoh et al. in 2004 revealed more than 146 different proteins including 
RBM5 present in the speckles.  Identification of RBM5 in the nuclear speckle 
proteomic and this study reinforces the idea that RBM5 is indeed a speckle protein.  
Also, a majority fraction (81%) of the 146 proteins identified by IGC proteomic 
analysis were previously associated with RNA metabolism including 51% involved in 
pre-mRNA splicing (Saitoh et al., 2004).  Studies in live cells have shown that 
nuclear speckle proteins are dynamic and not stationary as suggested by the images of 
fixed cells.  However, there is still a great deal of controversy regarding the role of 
nuclear speckles in transcription.  One school of thought suggests that nuclear 
speckles are merely store houses of splicing factors from which they are recruited to 
active sites of transcription, the perichromatin fibrils (Lamond and Spector, 2003).  
Contrary to this viewpoint, several groups have reported colocalization of pre-mRNA 
transcripts of highly transcribed genes with nuclear speckles.  However, this 
phenomenon appears to be gene specific and is not seen for all highly transcribed 
genes (Smith et al., 1999; Shopland et al., 2002).  Undoubtedly, resolving the issue of 
the presence or absence of nascent transcripts within the nuclear speckles will in part 




As discussed before, RBM5 proteins are well conserved across the species and 
also shares considerable homology with another RNA binding protein-RBM10.  In 
addition to the two bipartite nuclear localization domains (NLS), the multi-modular 
structure of RBM5 contains a G-patch domain along with two RNA binding (RRM) 
and two zinc finger domains, which might function in defining its subnuclear 
localization in speckles.  This study also aimed at discerning the role of the two 
bipartite NLS at the N- and the C-terminal ends of full-length RBM5 protein.  Site-
directed mutagenesis and subsequent transient transfection studies of the two bipartite 
nuclear localization signals, NLS1 (N-terminal) and NLS2 (C-terminal) demonstrated 
that RBM5 relies on only one NLS for its nuclear targeting.  Mutations in NLS1M 
had no effect on either the nuclear targeting or localization of RBM5 within the 
speckles.  Subsequent SC35 colocalization and transcriptional inhibition studies gave 
results comparable to those obtained for unmutated RBM5.  On the other hand, 
disruption of the C-terminal NLS (NLS2M) completely abolished nuclear localization 
of RBM5.  Recombinant proteins with both the NLS mutated also displayed similar 
mislocalizations as expected.  Surprisingly, the mislocalized proteins were targeted to 
lysosomes instead of proteasomes as expected.  Localization of mislocalized proteins 
(EGFPRBM5NLS2M and EGFPRBM5NLS1MNLS2M) to lysosomes was confirmed 
by staining the acidic organelles with LysoTracker Red DND-99.  The mislocalized 
proteins colocalize with only a part of the stained acidic organelles, confirming that 
the observed colocalization was not due to channel cross-talk.  Autofluorescence and 




A literature survey reveals that overexpressed or mislocalized proteins are 
dislocated from the endoplasmic reticulum to the cytosol where they are usually 
degraded by proteasomes in a ubiquitin dependent or independent manner.  Massive 
loads of the mislocalized or aggregated proteins which cannot be rapidly degraded by 
ubiquitin-proteasome pathway are aggregated into inclusion bodies known as 
aggresomes which then might integrate with lysosomes for degradation (Kopito, 
2000).  Macromolecular or protein degradation by lysosomes can take place through 
multiple pathways such as macroautophagy (organelles), crinoautophagy (secretory 
proteins), heterophagy (endocytosis of plasma membrane proteins), microautophagy 
or chaperone-mediated autophagy (Knecht and Salvador, 2005).  In chaperone-
mediated autophagy cytosolic proteins are directly transported inside the lysosomes 
for degradation via the action of chaperone hsc73 and lamp2a receptor.  A variety of 
signal sequences specific for lysosomal targeting such as KFERQ in cytosolic 
proteins and NPXY, YXXØ, [DE]XXXL[LI] or DXXLL (X is any amino acid and Ø 
is an amino acid with a bulky hydrophobic side chain) in transmembrane proteins 
have been discovered so far (Bonifacino and Traub, 2003; Knecht and Salvador, 
2005).  However, the exact mechanism by which mutated RBM5 with non-functional 
NLS is targeted to lysosomes is not clear.  A recent study has shown that 
ubiquitinated Jun is primarily targeted to lysosomes and can be cosedimented with a 
lysosomal hexosaminidase activity.  In this case the PPVY signal sequence mediates 
the ubiquitination of Jun by E3 ligase or Itch (Fang and Kerppola, 2004). 
Thus, from the site-directed mutagenesis experiments it is clear that the C-




result concurs with a previous observation by Edamatsu et al. that the N-terminal half 
of RBM5 protein fails to localize to nucleus.  Two scenarios for the N-terminal NLS 
(NLS1M) can be speculated – either the NLS1 even though well conserved is non-
functional or alternatively it is cryptic or unexposed.  If indeed, the N-terminal NLS is 
non-functional it is extremely tempting to speculate that all of the RBM5 splice 
variants, none of which possess the C-terminal NLS, will fail to colocalize in nuclear 
speckles.  The fact that protein products for some of the splice variants have not been 
observed so far suggests that their role is deviant from the common function of 
translation to a protein product.  As mentioned before, VEGF treatment of endothelial 
cells induced the expression of full-length RBM5 transcripts, but had no effect on the 
7.4 kb transcript encoding the splice variants.  Clearly, future studies to determine the 

















CONCLUSIONS AND FUTURE STUDIES 
 
 
The growth of blood vessels or vasculature plays a central role in many 
physiological and pathological conditions.  Understanding the mechanisms fine-
tuning angiogenesis through the study endothelial cells, a key component of blood 
vessels, has been a focus of intense research.  Vascular endothelial growth factor 
(specifically VEGF-A) is a pro-angiogenic growth factor that performs a vital role in 
angiogenesis.  Unraveling the signaling cascades emerging from VEGF-A stimulation 
of endothelial cells has provided valuable insights into the downstream effectors of 
angiogenesis.  At the onset of this project there was clearly one key research area 
neglected - the role of immediate early genes induced by VEGF-A.  Through this 
study I identified a unique set of 17 immediate early genes induced by VEGF-A, 
including several transcription factors, growth factors and also a putative tumor 
suppressor gene RBM5 (Chapter 2, Part I). 
RBM5 (RNA binding motif protein 5) was initially discovered as a part of 
chromosomal region 3p21.3 frequently deleted in various cancers.  Subsequent 
studies by Sutherland et al. (2000) and Oh et al. (2006) also implicated RBM5 and its 
splice variants as a regulator of apoptosis (Chapter 1, Part II).  The role of RBM5 as 
an immediate early gene induced by VEGF-A opened an entire new avenue of 




exciting opportunity to design an array of projects aimed at understanding the 
structure and function relationship of RBM5.  The gene RBM5 is well conserved 
across the species and also shares 51% homology with another RNA binding protein, 
RBM10.  The localization of RBM5 in SC35 stained nuclear speckles was confirmed 
in this study.  Nuclear localizations of RBM5 were completely abrogated by the 
disruption of the C-terminal NLS (NLS2) only.  The N-terminal NLS of RBM5 is 
probably non-functional or unexposed.  Non-functionality of the N-terminal RBM5 
concurs with the results obtained by Edamatsu et al. (2000) using deletion mutants 
fused to c-myc epitope.  Thus, now only the functional C-terminal NLS can be used 
to deduce the family of importins responsible for transporting RBM5 into the nucleus.  
Additionally, I suspect that RBM5 splice variants will fail to localize in the nucleus.  
This in turn raises intriguing questions regarding the physiological role and 
localization of these RBM5 splice variants.  Moreover, full-length RBM5 with 
mutated NLS2 unexpectedly mislocalized to lysosomes instead of proteasomes as 
revealed by dual fluorescent staining with LysoTracker Red.  Degradation of mono-
ubiquitinated transcription factors including Jun in lysosomes is well known.  
However, further experimentation to determine ubiquitination of RBM5 was 
hampered by the non-availability of RBM5 specific antibodies. 
Even though in this study RBM5 displayed absolute nuclear speckle 
localization, many RNA binding proteins are known to shuttle between the nucleus 
and cytosol.  The pEGFPRBM5 construct used in this study can be applied to design 
heterokaryon assays to detect any nucleo-cytoplasmic shuttling of RBM5.  




the same construct coupled with live cell microscopy.  Moreover, mutational analysis 
coupled with a reporter such as EGFP used in this study can aid in determining the 
domains responsible for localization of RBM5 specifically in nuclear speckles as 
opposed any other subnuclear site. 
 
ANGIOGENESIS/APOPTOSIS/TUMOR SUPPRESSOR GENE? 
 
Function of RBM5 in RNA metabolism can be speculated based on its 
localization in nuclear speckles and the presence of various domains such as RRM 
and G-patch domains.  Apart from being an IEG induced by a pro-angiogenic factor 
VEGF-A, RBM5 is also implicated to function as a tumor suppressor gene and an 
apoptotic regulator.  Identifying the family of RNA molecules it binds along with the 
development of knockout mice might help in deducing the function of RBM5 in these 
diverse roles.  Although, previous studies demonstrated that RBM5 selectively binds 
to poly (G) RNA homopolymer, further RNA binding studies are hampered by 
difficulties in production of full-length RBM5 protein in vitro and the commercial 
unavailability of RBM5 specific antibody.  Most of the popular methods designed to 
discern the RNA binding properties of proteins such as SELEX or SNAAP either 
require milligram quantities of the same protein or a specific antibody for 
immunoprecipitation studies.  Unfortunately, in the case of RBM5 none of these 
products were readily available.  Production of recombinant RBM5 with a GST 
(glutathione S-transferase) tag detailed in Appendix A is a huge step for future studies 




Site-directed mutagenesis of the various RBM5 RNA binding domains can be 
subsequently used to deduce the amino acids influencing the binding affinity of its 
RNA substrates.  Moreover, mutational analysis coupled with a reporter such as 
EGFP used in this study can aid in determining the domains responsible for 
localization of RBM5 specifically in nuclear speckles as opposed any other nuclear 
site. 
 
VEGF AND INDUCTION OF RBM5 
 
The induction of RBM5 by VEGF-A in endothelial cells raises another 
intriguing question regarding the signaling cascade involved.  I attempted to answer 
this question by using various signal transduction inhibitors coupled with quantitative 
real time RT-PCR to discern any changes in RBM5 gene expression (Appendix B).  
However, these studies were greatly hindered by not only the slow growth rate of 
HUVEC, but also by the low copy number of native RBM5 transcript and difficulty 
in finding a good control gene not affected by VEGF-A.  Despite these limitations a 
few conclusions affecting future studies to dissect the VEGF-A signal transduction 
pathway leading to RBM5 induction by various methods such as use of adenoviral 
constructs of constitutively active signal transducers or siRNA can be drawn from 
these experiments.  Clearly, novel methods for equalizing gene expression 
experiments instead of relying on the standard housekeeping genes which are equally 





OTHER IMMEDIATE EARLY GENES 
 
Although, this study focused mainly on RBM5, understanding the role of the 
remaining 16 immediate early genes will undoubtedly play a vital role in piecing 
together the big picture of angiogenesis.  During the course of this study only a few of 
the immediate early genes such as COX-2, EGR2, ETR101 and ATF3 have been 
reported to be induced by VEGF-A.  However, the overall role of the various 
immediate genes including many transcription factors identified and their 
downstream effectors is yet to be discovered.  Understanding the mechanisms of 
VEGF-A induced angiogenesis and its downstream modulators may help in fine-
tuning the derailed proliferation of blood vessels in various pathological conditions 









PRODUCTION OF FULL-LENGTH RBM5 AND DEVELOPMENT OF 





As discussed before, RBM5 an immediate early gene induced by VEGF-A is 
also implicated to play a role in apoptosis and may also function as a tumor 
suppressor gene.  In addition to the two bipartite NLS, RBM5 also contains two RRM 
domains, a G-patch domain and two zinc finger domains.  Based on the presence of 
these domains and the fact that RBM5 localizes in nuclear speckles enriched in 
splicing factors, it may be deduced that RBM5 functions in RNA metabolism.  
Moreover, identifying the family of RNA substrates bound by RBM5 may provide an 
invaluable insight on the function of RBM5 as a TSG, in apoptosis and angiogenesis. 
Loss of function of RNA binding proteins DAZ (deleted in azoospermia) and 
FMRP (fragile X mental retardation protein) have been shown to be important in 
genetic disorders azoospermia and fragile X mental retardation, respectively.  
Myotonic dystrophy on the other hand is caused due to the unusually tight binding 




the 3’ UTR of mutant myotonin protein kinase (DMPK) transcript, leading to aberrant 
processing of other CUGBP1-RNA substrates and manifestation of myotonic 
dystrophy (Rodgers et al., 2002; Sung et al., 2000).  Thus, even though RNA binding 
proteins play a very important role in processing and turnover of RNA, relatively 
little is known about their function (Trifillis et al., 1999).  A major hurdle faced in 
studying the function of an RNA binding protein is to resolve the RNA substrates that 
bind to it.  Traditional methods such as SELEX (systemic evolution of ligands by 
exponential enrichment) and its variations can be used to resolve this problem.  
SELEX involves multiple rounds of PCR amplification and subsequent selection of 
the strongest binding RNA substrate.  Although very powerful and utilized 
successfully in many cases, this method has two major drawbacks.  The RNA 
substrates used are short artificially synthesized RNA molecules.  Thus, the RNA 
substrates positively identified may not exist in vivo.  Another drawback is that only 
molecules which are bound directly by the RNA binding protein are recognized 
(Trifillis et al., 1999). 
To circumvent these problems, an alternative approach known as the SNAAP 
(specific nucleic acids associated with proteins) developed by Kiledjian et al. was 
chosen (Rodgers et al., 2002; Trifillis et al., 1999; Carr-Schmid, 2006).  This method 
utilizes the intact endogenous cellular mRNA associated with its mRNP, maintaining 
the RNA-protein interaction occurring in vivo, followed by microarray or differential 
display analysis to identify the RNA substrate.  Thus, both direct and indirect binding 
of RNA substrates to RBM5 can be discerned (Trifillis et al., 1999).  False positive 




eliminated by carrying out the analysis in parallel for protein of interest and another 
unrelated RBP.  Thus, RNA molecules bound by both RBPs are probably false 
positives and are eliminated.  Whereas, RNA molecules bound by one RBP only, 
most likely reflect its true RNA binding properties. 
Efficacy of SNAAP was tested by the authors on existing RNA-protein 
interaction of mDAZL (murine autosomal deleted in azoospermia-like protein) with 
Tpx-1 and Cdc25A mRNAs and α complex protein 1 (αCP1) stabilizing human α-
globin mRNA.  In case of αCP1, the method not only identified the existing RNA 
protein interactions but also identified two new interactions with TAPA-1 and cox-2 
mRNAs.  All the results were further confirmed by studying direct interaction 
between the αCP1 and TAPA-1/coxII mRNAs using EMSA (electro-mobility shift 
assays) (Trifillis et al., 1999; Carr-Schmid, 2006). 
However, in this study production of full-length RBM5 protein tagged to 
biotin (pPinpoint vector) in E.coli cells resulted in approximately 20 pre-maturely 
truncated products with very little full-length RBM5.  It was hypothesized that 
presence of two to three consecutive arginine residues (an amino acid with rare tRNA 
in E.coli cells) throughout the sequence might have led to the pre-mature termination.  
Unfortunately, the problem of production of truncated products did not improve even 
in the presence of a helper plasmid pSJS1240 encoding rare E.coli tRNAs – a kind 
gift from Dr. Cameron, Pennsylvania State University (Kim et al., 1998).  Therefore, 
I decided to attempt production of full-length RBM5 protein in Sf9 insect cells which 
mirror eukaryotic systems more closely than prokaryotes.  A GST (glutathione S-




charged His residues may interfere with the RNA binding (Trifillis et al., 1999).  The 
GST-RBM5 fusion protein expression is controlled by a strong AcNPV (Autographa 
californica) polyhedrin promoter.  Indeed, it was possible to produce full-length 
RBM5 protein in these cells, a big step forward in an attempt to discern the RNA 
binding properties of RBM5.  Since RBM5 is a nuclear speckle protein nuclear 
extracts from HT-6 cells were produced as a source of RNA substrates for SNAAP 
assay. 
Unfortunately, due to technical difficulties and the length of time needed to 
conduct SNAAP analysis beginning from full-length protein production, a project 
worth another dissertation in itself, it was not possible to uncover the identity of RNA 
species bound by RBM5. 
 
 
MATERIALS AND METHODS: 
 
Cell Culture 
The Sf9 (ATCC) insect cell line established from ovarian tissues of 
Spodoptera frugiperda larvae (ATCC) was grown in either Grace’s Insect cell or 
TNM-FH media (Invitrogen or Sigma Aldrich) supplemented with 5% fetal bovine 
serum at 28°C.  The cells were passaged as soon as they reached 80% confluence 






Recombinant plasmid production and Sf9 transfection 
Construction of pACG3XRBM5 vector – A baculovirus transfer vector 
encoding GST expression-pAcG3X (PharMingen, BD Biosciences) was modified to 
include Sac I (GAGCTC) restriction site.  The adaptor carrying the Sac I restriction 
site was designed by annealing two oligonucleotides: 
1) G3XSACD (5' GATCCCCTCAGAGCTCGGG 3') 
2) G3XSACU (5' AATTCCCGAGCTCTGAGGG 3). 
The annealing reaction (10 µl) was carried out as follows: 
G3XSACD (476 µM)      2 µl 
G3XSACU (430 µM)      2 µl 
10X Advantage 2 PCR buffer (Clontech)   1 µl 
The reaction was heated to 94ºC and allowed to cool gradually at room temperature.  
The annealing reaction was further diluted (1:100) and used to generate pAcG3X-Sac 
I vector by performing a ligation reaction as below: 
(BamH I - EcoR I) CIP dephosphorylated pAcGX vector 1µl (100 ng) 
Annealed product (1:100)     1 µl 
10X T4 DNA ligase buffer (Promega)   1 µl 
T4 DNA ligase      1 µl 
dH2O        6 µl 
Ligation reaction was incubated overnight at 16ºC.  Competent JM109 (Promega) 
cells were transformed with the above ligation reaction and plated on LB agar plates 
containing 100 µg/ml ampicillin.  After, overnight incubation recombinant colonies 




ligations as described before (Chapter 2, Part II).  The RBM5 coding sequence 
spliced out from pEGFPRBM5 (Sac I - EcoR I) and gel purified using DEAE 
membrane (Chapter 2, Part 1) was used as a template for the ligation reaction set up 
as below to generate pAcG3XRBM5: 
(Sac I - EcoR I) CIP dephosphorylated pAcGX vector 1µl (60 ng) 
(Sac I - EcoR I) RBM5      1µl (40 ng) 
10X T4 DNA ligase buffer (Promega)   1 µl 
T4 DNA ligase      1 µl 
dH2O        6 µl 
Ligation reaction was carried out as mentioned before.  Competent JM109 cells were 
transformed with the above ligation reaction and plated on LB agar plates containing 
100 µg/ml of ampicillin.  After, overnight incubation recombinant colonies were 
processed for plasmid isolation and sequenced to confirm the orientation of ligations 
as described before.  Two recombinant pAcG3XRBM5 clones (#5 and #13) were 
selected and grown overnight in 100 ml of Terrific broth containing 100 µg/ml 
ampicillin at 37°C/200 rpm.  Plasmid midipreps were carried out by alkaline lysis 
method (Sambrook et al., 1989).  Purity of the isolated DNA was confirmed by 
measuring 260/280 absorbance ratio and agarose gel electrophoresis.  The plasmid 
minipreps were further purified twice using cesium chloride density gradient 
(containing ethidium bromide) centrifugation as mentioned in Sambrook et al., 1989.  
Isolated plasmid bands were extracted five times with water saturated 1-butanol and 
subsequently precipitated by ethanol twice.  The plasmid pellets were then dissolved 




detailed in the next section.  All subsequent procedures were carried out for pAcG3X 
empty vector and both the pAcG3XRBM5#5 and pAcG3XRBM5#13 clones, in 
parallel. 
Transfection of Sf9 cells - For construction of recombinant virus co-
transfection experiments in Sf9 (S. frugiperda) insect cells with purified plasmids 
(pAcG3XRBM5#5, pAcG3XRBM5#13 and pAcG3X) and linearized baculovirus 
DNA (BacPAK6 DNA Bsu36 I digest, Clontech) was carried out.  All procedures for 
transfections including control were carried out as detailed in the Clontech manual 
PT1260-1.  Briefly, 5 µl of each plasmid (100 ng/µl) and linearized baculovirus DNA 
were suspended in 86 µl of water and 4 µl of Bacfectin (Clontech) and incubated for 
15 minutes at room temperature.  The reaction was subsequently layered onto Sf9 
cells and further incubated for five hours at room temperature.  After five hours of 
incubation additional media was added and plates were incubated further at 28ºC until 
the positive control plate developed a blue color.  Media from all the plates 
containing recombinant viruses was transferred after five days and stored in 15 ml 
Falcon tubes at 4ºC. 
 
Plaque Assay to purify recombinant viruses 
Plaque Assay - All plaque assays were carried out in six well tissue culture 
plates.  Briefly, each well was seeded with Sf9 cells (95% viability) until 50% 
confluent in 2 ml of TNM-FH medium without any additives.  Subsequently, each 
well was infected with 100 µl of individual dilution for each plasmid (10-4, 10-5, 10-6, 




28ºC.  The media was then replaced with 2 ml of 1% low melting Sea-Plaque agarose 
dissolved in Grace’s Insect cell medium.  The plates were further incubated for eight 
days at 28ºC.  Plaque clearings were observed by staining the plates with 0.03% 
neutral red solution for 2-3 hours at 28ºC.  The stain was then removed and the plates 
were further incubated overnight for plaques to clear. 
Virus Propagation – Individual plaques were picked up using sterile Pasteur 
pipettes and re-suspended in individual sterile microcentrifuge 1 ml TNM-FH 
medium containing 5% FCS.  The tubes were rotated overnight at 4ºC to elute virus 
from agarose plugs.  In total, 30 plaques (10 each for pAcG3XRBM5#5, 
pAcG3XRBM5#13 and pAcG3X) were picked.  Viruses in each plaque elute (100 µl) 
were further amplified by infecting fresh Sf9 cells seeded in TNM-FH medium with 
5% FCS in six-well plates.  All plates were incubated at 28ºC until cells displayed 
cytopathic effects.  Cells were harvested and cell pellets were further processed for 
western analyses (see below) to determine protein production.  These secondary 
amplification supernatants were stored at 4ºC and used for protein production as 
detailed in the next section.  Titers of secondary amplifications were determined 
using rapid titer assay (Clontech).  Subsequent, high titer viral stocks for protein 
production were made by infecting Sf9 cells with secondary amplification stocks at an 
MOI of less than one. 
 
Protein production 
Sf9 cells grown as suspension cultures with more than 95% viability were 




with 30 ml of fresh TNM-FH.  The cells were then infected at an MOI of 5 and 
incubated at 28ºC for three days for protein production.  Cells were harvested and 
centrifuged at 10,000g for 5 minutes.  The supernatant was subsequently discarded 
and cell pellets containing the recombinant protein were stored at -20ºC.  Protein 
production for RBM5 and RBM5GST was done in Sf9 cells.  E.coli cells were used to 
produce αCP1GST protein – a kind gift from Dr. Kiledjian (Trifillis et al., 1999; 
Kiledjian et al., 1999).  Protein extracts in lysis buffer (Appendix B) were prepared 
by nitrogen cavitation in presence of cocktail of EDTA free protease inhibitors 
(Roche Applied Science). 
 
Western analysis 
Approximately, 30-50 µg of cell pellet dissolved in 1X Laemmli buffer were 
boiled for five minutes and subsequently separated on 7.5% SDS-PAGE gels 
(Laemmli, 1970).  Amount of recombinant protein was quantified by running 100 ng 
GST (Santa Cruz Biotechnology) on the same gel along with molecular weight 
markers (Sigma Aldrich).  The gel was transferred onto a nitrocellulose membrane for 
4 hours/220 mAmps/4ºC as detailed in Sambrook et al. 1989.  The membrane was 
then air dried overnight and subsequently blocked for 1 hour in 10 ml of BlottoA (5% 
w/v non-fat dry milk in TBST).  Primary monoclonal anti-GST antibody (50 µl in 10 
ml BlottoA) (sc-138, Santa Cruz Biotechnology) was added to the membrane and 
further incubated for another hour.  The membrane was then washed thrice in 10 ml 
of TBST (Appendix B) and incubated for one hour in 10 ml of BlottoA containing 10 




then washed thrice in 10 ml of TBST and TBS each for five minutes and developed 
by Pierce ECL western blotting substrate for one minute (Pierce Biotechnology) for 
chemiluminescent detection.  Membranes were blotted dry and exposed to BioMax 
X-ray films (Kodak) for one and five minutes. 
 
Preparation of nuclear extracts 
HT-6 (SV40 large T antigen transformed HUVEC) cells were grown in EGM 
medium as previously described for HUVEC cells (Chapter 2, Part I).  Preparation of 
nuclear extracts from HT-6 cells was done as described in CelLyticTM NuCLEARTM 




RESULTS AND DISCUSSION 
 
Production of recombinant proteins 
Detection of RNA binding protein substrates is a major step in defining its 
function.  Unfortunately, in case of RBM5 this process was hampered by the 
unavailability of pure isolated protein.  As mentioned before RBM5 protein 
production in prokaryotic system resulted in 20-25 bands representing early 
truncation products with minimal amount of full-length product.  Binding assay 
techniques such as SELEX and SNAAP designed to select RNA species bound by the 




cross-linking methodologies require a protein specific antibody, which was also 
commercially unavailable for RBM5. 
Switching the host system from prokaryotic to insect cell cultures resulted in 
the production of full-length RBM5 protein.  However, as seen from the western 
analysis (figure 26) two distinct clones, one producing full-length RBM5 and other 
resulting in truncated products (lanes 3 and 9) were observed.  Large-scale production 
of full-length RBM5GST protein was also done successfully for two (#13PP1T1 and 
#5PP4T1) of the twenty plaque picks selected.  The expected molecular weight of 
full-length RBM5 and RBM5GST proteins is 92 kDa and 118 kDa respectively.  
However, since the molecular weight of RBM5GST is higher (figure 26) than 
predicted, it is very likely that the RBM5 undergoes post-translational modifications.  
Western analysis of RBM5 by Sutherland et al. also showed similar results.  
Additionally, it is unlikely that the GST tag in RBM5GST undergoes any 
modifications since the predicted and the observed molecular weight of GST 
produced in insect cells on western blots is the same (figure 27A). 
Elimination of false positive RNA binding in SNAAP analysis is done by 
running the experiments in parallel for two other controls, GST and αCP1GST.  
Polycytidylate-binding protein αCP1 was chosen in this study for two reasons.  
Firstly, αCP1 contains KH domains a different RNA binding domain as compared to 
the RRM domains present in RBM5.  Secondly, as the name suggests αCP1 
preferentially binds to poly (rC) instead of poly (rG) as displayed by RBM5.  Thus, 
any RNA substrates bound by both proteins with different characteristics are probably 
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necessary to eliminate any RNA molecules bound by the two RBP fusion constructs.  


















Figure 26:  Western blot probed with anti-GST antibody.  Cell pellets obtained during 
secondary amplification of four different RBM5GST plaque picks on day two and 
three of incubation are displayed in lanes 1-4 and lanes 7-10, respectively.  
Production of recombinant RBM5GST protein from high titer stocks after day two 
and three of incubation are shown in lanes 5-6 and lanes11-12, respectively.  High 
titer stocks were produced for two different clones, #13PP1T1 (lanes 5 and 11) and 
#5PP4T1 (lanes 6 and 12).  Molecular weights of pre-stained protein ladder are 
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Figure 27:  Production of two control proteins glutathione S-transferase (pAcG3X) in 
Sf9 insect cells and αCP1GST protein in E.coli cells is shown in two western blots 
probed with anti-GST antibody.  The molecular weight of the 26 kDa GST produced 
in insect cells (right side of blot A) concurs with the commercially available control 
GST (100 ng, left side of blot A).  Protein production for 62 kDa αCP1GST protein 
was carried out in E.coli cells as detailed by Trifillis et al., 1999.  Molecular weights 










Determination of RNA substrates bound by any of RNA binding protein is 
vital for determining its probable function.  Popular techniques require either 
milligram quantities of proteins (SELEX, SNAAP) or require antibodies with high 
binding affinities against the protein of choice, both of which were unavailable for 
RBM5.  RNA binding studies for RBM5 were further hampered by the difficulty in 
producing full-length RBM5 protein in the commonly used prokaryotic systems.  This 
experiment establishes a protocol for successful production of full-length RBM5 
protein in insect cells using baculoviral vectors.  Two other control proteins GST and 
αCP1GST necessary to rule out false positives in SNAAP analysis were also 
successfully produced.  Production of full-length RBM5 defines the first key step 
necessary to experimentally deduce its RNA substrates.  The same system can also be 
further used to introduce mutations in the two RRM domains to discern the amino 






DISSECTION OF VEGF-A/VEGFR SIGNAL TRANSDUCTION CASCADE IN 





Stimulation of normally quiescent endothelial cells by pro-angiogenic cytokine 
VEGF-A is a key step in both physiological and pathological angiogenesis.  Induction of 
immediate early gene RBM5 within an hour in endothelial cells stimulated by VEGF-A 
was confirmed by northern analysis (Chapter 2, Part I).  As discussed in Chapter 1 (Part 
I) the signal transduction cascade emerging from the stimulation of endothelial cells by 
VEGF-A has been delineated.  Various pathways such as PI3K, MAPK and p38 MAPK 
are implicated in apoptotic survival, proliferation and migration of endothelial cells, 
respectively (Karkkainen et al., 2002; Chapter 1, Part I).  Despite the fact that the VEGF-
A/VEGFR signaling pathways have been defined, the downstream effectors and the 
manner in which VEGF regulates these functions in endothelial cells is unclear.  Thus, 
defining the signaling cascade leading to the induction of the putative tumor suppressor 
gene and an apoptotic regulator RBM5 would represent an exciting avenue to categorize 
the function of RBM5 in the big picture of angiogenesis. 
The use of pharmacological inhibitors is one of the quickest ways to get the initial 




question.  Typically, serum starved cells (HUVEC) are pre-treated with inhibitors, 
usually four to five times the IC50 or Ki value followed by stimulation with growth factor 
(VEGF-A) (Liu et al., 2003; Calbiochem Inhibitor SourceBook™).  Down- or up-
regulation of RBM5 gene expression in presence or absence of inhibitors and VEGF can 
then be quantified by real time PCR with respect to the quantity of a stable house-keeping 
gene (Bustin et al., 2005).  Although, initially this approach seemed reasonably simple, 
this project was greatly hampered by two main factors.  Firstly, most of the house-
keeping genes commonly used for normalization of RNA quantity were also up-regulated 
by VEGF thus, negating any discernment of RBM5 induction in HUVEC.  Secondly, the 
slow growth of HUVEC cells in vitro also limited the number of repetitions that could 
performed for each inhibitor condition in a limited time frame thereby, making it 
impossible to conduct any further non-parametric statistical analyses (Tichopad et al., 
2006).  Despite these limitations the initial data obtained in this study can be vital to 
design further experiments using various other techniques such as, RNAi or constitutively 
active or inactive adenoviral vectors to discern the upstream signaling regulators. 
 
 
METHODS AND MATRIALS 
 
Cell culture and inhibitor treatments 
HUVEC cell culture and VEGF-A induction studies were carried out as detailed 
in methods and material section of Chapter 2 (Part I).  For inhibitor studies, HUVEC cells 
were pre-treated with respective concentrations of pharmacological inhibitors for 30 




presence of inhibitors.  Controls consisted of cells treated with an equivalent 
concentration of carrier (dimethyl sulfoxide/DMSO) used to make up inhibitor stock 
solutions and inactive analogs of inhibitors when available.  List of inhibitors and the 
concentrations used as determined by literature survey and IC50 or Ki values is given in 
the table below. 
 
 Inhibitors used 
Ki/ 
IC50 
Conc. used Dissolved in 
Signaling response 
targeted 
1. LY294002 1.4 µM 5-30 µM DMSO PI3K activation 
2. LY303511 ≥100 µM 5-30 µM DMSO Inactive analog of LY294002 
3. Wortmannin 5 nM 0.1-1 µM DMSO PI3K activation 
4. PD98059 2-7 µM 10-20 µM DMSO MEK1/2 activation 
5. U0126 10 µM 40-100 µM DMSO MEK1/2 activation 
6. U0124 - 40-100 µM DMSO Inactive analog of U0126 
7. SB220025 60 nM 1-10 µM DMSO p38 MAPK (α and δ isoforms) 
8. SB202190 100 nM 5-10 µM DMSO p38 MAPK (α and β isoforms) 
9. Gö6983 7-60 nM 1-3 µM DMSO PKC activation except PKCµ 
10. Bisindolylmaleimide I HCl 10 nM 0.2-3 µM DMSO PKC activation 
11. BAPTA/AM N/A 10-50 µM DMSO Ca+2 mobilization 
12. SU5416 1 µM 10-20 µM DMSO VEGFR2 
13. L-NIO.2HCl 500 nM 10-50 µM EBM 0.5 eNOS 
14. L-NAME 500 nM 5-100 µM EBM 0.5 eNOS 
 
Table 6:  Concentrations of the inhibitors used in this study and the points of signal 
transduction cascades targeted are listed.  All inhibitor stock solutions were made up in 
DMSO (dimethyl sulfoxide) except for water soluble eNOS inhibitors which were 
dissolved in EBM 0.5.  All inhibitors were purchased from Calbiochem excluding 
SU5416 which was obtained from Sigma Aldrich.  IC50 values were obtained from the 





RNA isolation and cDNA production 
Media from the tissue culture plates was aspirated after respective VEGF-A or 
VEGF-A and inhibitor treatment.  Cells were immediately lysed using 3 ml of RNA Bee 
(Tel-Test) per 150 mm tissue culture dish (Corning).  Protocols for RNA isolation were 
carried out according to manufacturer’s directions and as detailed in Chapter 2 (Part I).  
Integrity of RNA was assessed by electrophoretic gel analysis of 28S and 18S rRNA 
bands and ratio of absorbance (greater than 2) obtained at 260 nm and 280 nm.  High 
capacity cDNA archive kit (Applied Biosystems) was used to reverse transcribe 5 µg of 
total RNA in a 50 µl reaction to cDNA (random primers) according to manufacturer’s 
directions.  The reverse transcription reaction was carried out at 37ºC for 120 minutes.  
The cDNA products were subsequently stored at -20ºC until used for estimation of gene 
quantification by real time PCR.  Total RNA from Raji cells (Clontech) was reverse 
transcribed in parallel and used for construction of standard curves as described in the 
next section. 
 
Real time PCR 
The following pre-made FAM labeled MGB probe and primer sets used in this 
study were obtained from Applied Biosystems: RBM5 (Hs00172952_m1), GAPDH 
(4333764F), HPRT1 (4333768F), cyclophilin A or PPIA (4333763F), 18S rRNA 
(4352930E).  Efficiencies of RBM5, HPRT1 and 18S rRNA real time PCR reactions 
were calculated from standard curves obtained by serialy diluting Raji cDNA.  Each real 
time PCR reaction was done in triplicates using cDNA corresponding to 100 ng of total 




















Universal PCR master mix (4304437) on the ABI Prism 7700 platform (Applied 
Biosystems).  Up- or down-regulation of RBM5 (target) with respect to housekeeping 
genes (reference) in presence or absence of inhibitors was calculated using the following 




Efficiency of the real time PCR reaction for both target (RBM5) and reference 
(housekeeping gene) is calculated as E=10[-1/slope].  The value of the slope is obtained 
by performing standard curve over three dilution range.  Both ‘control’ and ‘sample’ in 
the above equation represent the mean values of each condition done in triplicate.  The 
threshold value (Ct) is defined as the PCR cycle number when the fluorescence generated 
by the accumulated amplicons crosses the threshold.  This value is inversely proportional 
to the initial number of transcripts, thus higher the copy of a transcript, lower is the Ct 
value (Bustin, 2000). 
 
 
RESULTS AND DISCUSSION 
 
Selection of a suitable housekeeping gene for detecting induction of RBM5 
As mentioned before in the introduction section, selection of a suitable 
housekeeping gene to detect up-regulation of RBM5 was a major hurdle.  The simplified 




gene expression with respect to a normalized control was not used due to different PCR 
reaction efficiencies of RBM5 and housekeeping genes (see next section) (Thellin et al., 
1999; Livak and Schmittgen, 2001).  An ideal housekeeping gene must have following 
characteristics: 1) no changes in the expression level of transcripts under conditions of 
study, 2) have real time PCR efficiency close to that of gene under study and 3) also be 
present in approximately the same quantity as the target gene in study for equivalent 
reverse transcription kinetics.  Housekeeping genes commonly used to normalize RNA 
loading were also up-regulated in presence of VEGF-A similar to RBM5.  Thus, any gene 
quantification calculations for RBM5 normalized to housekeeping genes showed negative 
or no significant induction, contradictory to the induction by VEGF-A discerned clearly 
by northern analysis (Chapter 2, Part I).  Similar results were also obtained for GAPDH 
previously used in this study to normalize the quantity of total RNA in northern analysis.  
These disparate results might be attributed to two factors.  First, the efficiency of RBM5 
probe and primer set is lower as compared that of GAPDH which in turn reduces the 
value of numerator representing the induction of RBM5.  Secondly, the amount of 
GAPDH mRNA is considerably higher than RBM5 mRNA as seen from the significant 
difference in Ct values for the same RNA sample. 
In this study, five different housekeeping genes including glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), cyclophilin A or peptidylprolyl isomerase A 
(PPIA), 18S rRNA, hypoxanthine phosphoribosyl transferase 1 (HPRT1) and polymerase 
(RNA) II (DNA directed) polypeptide A (POLR2A) were examined.  Although, the 
quantity of POLR2A was similar to that of RBM5 transcript (similar Ct values), it was 




(figure 28A).  Similar results were seen for GAPDH and PPIA transcripts, both of which 
are represented by a higher number of transcripts than RBM5.  Two main housekeeping 
genes 18S rRNA and HPRT1 emerged as possible candidates to assess RBM5 gene 
induction.  Although, ribosomal RNA is known not to vary widely under conditions 
changing gene expression, the amount of 18S rRNA is significantly higher than the low 
copy number RBM5 transcript (Schmittgen and Zakrajsek, 2000; Bustin et al., 2005).  
This wide discrepancy in copy number can in turn lead to introduction of high assay 
variability which, can be in part circumvented by accurate measurement of total RNA 
(Bustin et al., 2005).  Assessment of both quality and quantity of total RNA isolated can 
be easily performed by newer techniques such as, Agilent 2100 Bioanalyser and LabChip 
technology, which were not available for this study (Bustin et al., 2005).  Thus, HPRT1 
was chosen as a housekeeping gene since it displayed a slightly lower Ct value than 
RBM5 and also displayed some RBM5 gene induction due to VEGF-A stimulation, 
although not comparable to that perceived by Northern analysis (figure 28B).  It is well 
known that low copy number genes such as HPRT1 and RBM5 are not efficiently 
converted to cDNA from RNA (Karrer et al., 1995; Bustin et al., 2005).  This in turn will 
result in faulty representation of gene up-regulation as detected by real time PCR, a trend 
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Figure 28:  Calculation of VEGF-A mediated RBM5 up-regulation by real time PCR 
analysis.  Data from individual experiments representing general trends of fold regulation 
of RBM5, observed with respect to various housekeeping genes examined in this study 
(A).  Efficiencies taken into account to calculate the regulation of RBM5 with respect to 
various housekeeping genes for various time points of VEGF-A stimulation are: 
GAPDH-1.8, PPIA-1.85, 18S rRNA-1.95, and HPRT1-1.84.  RBM5 efficiencies of 1.97 
and 1.73 were used for calculations with respect to GAPDH/PPIA and HPRT1 due to 
batch to batch variations between the probe and primer sets and reverse transcription 
kinetics.  All calculations were carried out by the formula listed in the Materials and 
Methods section except those for POLR2A which were calculated by the 2-ΔΔCt method.  
Difference in absolute RBM5 regulation as discerned by Northern (GAPDH control) 





y = -4.4056x + 32.248
R2 = 0.9887
y = -3.7807x + 29.351
R2 = 0.9971
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Efficiency calculations 
As mentioned before, various parameters such as, reverse transcription efficiency, 
quality of RNA, copy number of the gene and efficiency of the PCR reaction determine 
accurate and reproducible estimation of gene regulation by real time PCR analyses.  
Estimation of efficiency is an essential step to determine the dynamic range of the PCR 
reaction for a given probe and primer set of the target/housekeeping gene.  Efficiency of 
the PCR reaction is calculated by plotting a standard curve (log quantity of RNA vs. Ct) 
over a series of dilutions (figure 29).  Real time PCR efficiencies were calculated for all 











Figure 29:  RBM5 and HPRT1 standard curves.  Average threshold values for each 
individual dilution done in triplicates are plotted against the log value of cDNA in 
nanograms.  Efficiencies (E=10[-1/slope]) for RBM5 and HPRT1 were calculated as 1.69 
and 1.84, respectively.  The ΔCt values for each dilution was calculated and re-plotted on 
the same graph using linear regression analysis.  The 2-ΔΔCt method for estimation of gene 
regulation can only be used if the amplification efficiencies of target and reference genes 




Estimation gene up- or down regulation by the 2-ΔΔCt method requires the amplification 
efficiencies of both the target and the housekeeping genes to be equal.  This is easily 
determined by calculating the difference between the Ct values over the same range of 
dilutions used for constructing standard curves.  In this study however, the efficiencies of 
both RBM5 and HPRT1 are considerably different as discerned by the value of the slope 
of ΔCt curve significantly higher than zero (figure 29).   
 
Inhibitor studies 
Effect of various signaling pathways emerging from VEGF-A stimulation of endothelial 
cells (HUVEC) was evaluated by using two different pharmacological inhibitors targeting 
a single pathway wherever possible.  When available inactive analogs of pharmacological 
inhibitors and different concentrations of carrier (DMSO) were evaluated as controls.  
Up-regulation is denoted by a positive value in the fold regulation column.  However, 
since down-regulation is expressed as [1/expression ratio], the degree of inhibition can be 
assessed by the values in the ‘Absolute gene regulation’ and the ‘2-log regulation’ 
columns.  Threshold values for each condition for both HPRT1 and RBM5 were obtained 
by averaging the triplicate Ct values.  Outlier Ct values differing by ±0.5 Ct units within 
the same condition (done in triplicate) were discarded.  All values were calculated by 
using the Relative Expression software tool (REST) (Pfaffl et al., 2002).  I used as a 
working hypothesis that RBM5 induction is downstream of VEGFR2 activation, which is 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7:  Effect of various inhibitors on RBM5 gene induction by VEGF-A was 
evaluated by real time RT-PCR.  All calculations were done by plugging in triplicate 
values in the Relative Expression software tool (REST) developed by Pfaffl et al., 
2002.  Percent CV values calculated for HPRT1 and RBM5 average Ct values are not 
shown.  Up-regulation of RBM5 in endothelial cells by VEGF-A at various time 
points was calculated using the un-stimulated cells (0 hours) as control.  Conversely, 
effect of various pharmacological inhibitors was evaluated by using the Ct values 
obtained from the RNA samples isolated from endothelial cells stimulated with 
VEGF-A for 60 minutes.  Each set represents an independent experiment and each 






















Treatment of HUVEC cells with a VEGFR2 inhibitor (SU5416) negatively 
regulated the induction of RBM5 (-1.7 fold) transcript despite its significantly lower 
solubility in EBM 0.5 culture medium.  Regulation of RBM5 by the PI3K pathway 
was evaluated by using wortmannin and LY294002 and its inactive analog 
LY303511.  RBM5 was consistently down-regulated in the presence of 0.1-1 µM 
wortmannin (-1.1 to -1.83 fold) but showed a slight up-regulation in the presence of 
10 µM (1.07 fold) wortmannin which may be due to increased concentration of 
DMSO.  However, no conclusive results were obtained to assess the effect of the 
second PI3K inhibitor LY294002, which showed an up-and down regulation in two 
different experimental sets, respectively.  Moreover, the inactive analog of 
LY294002, LY303511 also displayed an overall down-regulation of RBM5 
expression ratio.  Similarly, evaluation of p38 MAPK in RBM5 induction by 
SB220025 and SB202190 was not possible due to conflicting results obtained.  
Although, SB202190 showed an overall down-regulation of RBM5, comparable 
down-regulation was not seen in the presence of SB220025. 
Inhibition of both PKC by Gö6983 and Bisindolylmaleimide I HCl (-1.1 to -
2.2 fold), and MAPK by PD98059 (-1.8 to -2.7 fold) significantly diminished any 
induction of RBM5 by VEGF-A.  Unfortunately, effect of MAPK pathway on RBM5 
induction by a second inhibitor U0126 and its inactive analog U0124 could not be 
ascertained due to extremely high HPRT1 Ct values (close to 40).  Similar problems 
were also encountered in experiments designed to study the effect of intracellular 
calcium flux on induction of RBM5 using BAPTA-AM.  This problem may occur if 




number HPRT1 transcript.  Additionally, amplification of low copy number genes in 
any given total RNA isolate by PCR is inherently difficult (Bustin et al., 2005).  
Surprisingly, treatment of endothelial cells with eNOS (endothelial nitric oxide 
synthase) inhibitors L-NIO (1.6 fold) and L-NAME (1.1 to 3.2 fold) further up-
regulated the level of RBM5 transcripts as compared to that in presence of VEGF-A 
alone.  Moreover, this observation is not false positive since, eNOS inhibitors were 
dissolved in basal cell culture medium and not DMSO. 
Thus, in summary it appears that PKC, MAPK and PI3K pathways emerging 
from the activated VEGFR2 may be the up-stream regulators of RBM5.  However, 
role of p38 MAPK and intracellular calcium could not be confirmed in this study.  
Additional up-regulation of RBM5 by inhibiting eNOS was another intriguing 
observation made in this study.  It must be noted however that these results are not 
conclusive but do offer vital clues about possible regulation of RBM5 by VEGF-A.  
No doubt further studies aimed at dissecting the signal transduction pathway leading 














REAGENTS AND MEDIA COMPOSITIONS 
 
 
TE (Tris EDTA) Buffer: 
10mM Tris-HCl (pH 7.4), 1mM EDTA 
 
Solution D: 
4M guanidine thiocyanate, 25mM sodium citrate (pH 7.0), 0.5% Sarkosyl, 0.1M  
2-Mercaptoethanol (added fresh) 
 
EGM: 
MCDB 131 (Sigma-Aldrich), 2% bovine fetal calf serum (Invitrogen), 1 μg/ml 
hydrocortisone (Sigma-Aldrich), 5 μg/ml heparin (Sigma-Aldrich), 10 ng/ml 
epidermal growth factor (Invitrogen), 50 units/ml penicillin, 50 μg/ml streptomycin 
(Invitrogen), 200 ng/ml amphotericin B (Sigma-Aldrich), 1 ng/ml basic fibroblast 
growth factor (Invitrogen) 
 
EBM 0.5: 
MCDB 131 (Sigma, MO), 0.5% bovine fetal calf serum (Invitrogen), 5 μg/ml heparin 
(Sigma), 50 units/ml penicillin, 50 μg/ml streptomycin (Invitrogen), 200 ng/ml 
amphotericin B (Sigma) 
 
20X SSC: 
3M NaCl, 0.3M sodium citrate, pH 7.0 
 
Denhardt’s reagent: 




150 ml 20X SSC, 6 ml 0.5M EDTA, 30 ml 100X Denhardt’s reagent, 12 ml 1M 
NaPO4 (pH 7.0), 81 ml distilled water, 60 g Dextran sulfate 
 
5X RNA formaldehyde gel running buffer: 
0.1M MOPS, 40mM sodium acetate, 5 mM EDTA in DEPC treated distilled water 
 
Formaldehyde gel loading buffer: 






10mM Tris HCl (pH 7.4), 150 mM NaCl 
 
TBST: 
TBS with 0.05% Tween 20 
 
High Salt Buffer: 
50mM Tris HCl, 1M NaCl, 10mM EDTA 
 
Pre-hybridization Solution: 
300 ml 20X SSC, 12 ml 0.5M EDTA, 120 ml 100X Denhardt’s reagent, 108 ml 
distilled water, 60 ml 1M NaPO4 (pH 7.0) 
 
FSS: 
450 ml formamide, 45 ml 10% SDS, 9 ml (10 mg/ml) single stranded DNA 
 
LB (Luria Bertani) Medium: 
10 g Tryptone, 5 g yeast extract 10 g NaCl, distilled water to 1000 ml, pH 7.0 
 
LB-Amp plates: 
LB medium supplemented with 1.5% agar.  Ampicillin (100 µg/ml) added after 
cooling to 50ºC 
 
Phosphate Buffered Saline: 
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4, distilled water to 1 L, pH 7.4 
 
1X Laemmli Buffer: 
50 mM Tris, pH 6.8, 10% glycerol, 2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 
1% 2-Mercaptoethanol (added fresh) 
 
Lysis Buffer: (Kiledjian et al., 1999) 
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